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ABSTRACT 
Cell counting finds many applications in diagnostics of many diseases. One of the most 
common tests recommended by the physicians is complete blood cell count (CBC). In 
chemotherapy and radiation therapy, the blood cell production needs to be monitored. 
Inflammation, leukemia, tissue injury, bone marrow failure and immunodeficiency can be 
identified by the irregular WBC counts and their differentials. Thus, a microfluidic, 
disposable, economical CBC would help in monitoring all these diseases with more 
efficiency and care. Cell counting in general, and ability to count the specific cells, would 
greatly help in clinical diagnostics. Currently, flow cytometers and hematology analyzers 
are used for this purpose, but they have not been able to penetrate in the resource-limited 
settings around the world because of being expensive and because they require trained 
technicians to operate. Over many years, people have developed microfluidic devices for 
cell counting, which could provide a portable and economical solution to the problem of 
cell counting at point-of-care.  
In this dissertation, we present a technique for counting the white blood cells and 
differentiating some of its sub-types within a microfluidic device. Starting with the whole 
blood, the red blood cells are lysed by saponin and formic acid. Quenching solution 
composed of phosphate buffer saline is infused in the device to halt the lysing process 
and maintain the pH of the solution. The remaining white blood cells are then passed 
across microfabricated electrodes within a microfluidic channel. The impedance is 
measured at 303 kHz and 1.7 MHz signals. Cells are captured in a capture chamber 
where the specific antibody is immobilized. The remaining cells are counted again and 
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the difference in cell counts give the number of captured cells. We have counted CD4 and 
CD8 T cells from our biochip using healthy and HIV infected blood samples. The cell 
counts from the biochip are compared with those from the flow cytometer, showing the 
high correlation between the two techniques. We have also characterized the coincidence 
detection and show that cell counting with coincidence detection improves the accuracy 
of the counting results.  
We have translated this technology to perform a complete blood cell (CBC) count 
from a drop of blood. The total leukocyte count and its 2-part differential (lymphocytes, 
monocytes + granulocytes) were obtained with the single counter. The blood sample is 
initially lysed, and then quenched, to get the total leukocyte count. At the entrance 
counter, lymphocytes can be electrically differentiated from monocytes+ neutrophils. We 
have used blood samples from healthy donors, patients admitted to the intensive care unit 
(ICU) and patients undergoing chemotherapy to get the complete dynamic range of cells. 
Erythrocytes and platelets have a very high concentration in the blood sample and require 
sample dilution for accurate cell counting. Platelet counting was more challenging using 
the same aperture counting channel because of the 1-2 µm diameter of platelets. We 
optimized the electronic settings to suit the platelet counting. We have performed on-chip 
blood dilution with PBS and performed erythrocyte and platelet counting. We have 
proposed that the same setup can be used in the future for reticulocyte counting that 
measures the health of bone marrow, especially for individuals undergoing 
chemotherapy.  
For the next step in translating our differential immuno-capture technology, we 
have explored the sepsis diagnosis application. Increased expression of the CD64 antigen 
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on the neutrophils is a biomarker for early diagnosis of sepsis. However, to use our 
technology to count CD64 neutrophils, as a first step, using blood samples collected from 
patients admitted to ICU we have shown a high correlation of the CD64 antigen 
preservation on the neutrophils and monocytes after they get treated with saponin and 
formic acid lysing buffer.  We have also done capture optimization studies and have 
shown that the percent capture is correlated to the expression level of the CD64 antigen 
on the cells. In the future, a complete blood cell count will be integrated with the sepsis 
CD64 capture differential counter in a single chip.  
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CHAPTER 1 
INTRODUCTION 
1.1.  Introduction to Cell Counting 
Cell counting finds many applications in diagnostics of many diseases. One of the most 
common tests recommended by physicians is the complete blood cell count (CBC).  Cell 
counting would be highly useful in acute radiation syndrome (ARS), where white blood 
cell (WBC) differential is required for its rapid management of the disease. In 
chemotherapy and radiation therapy, the blood cell production needs to be monitored. 
Inflammation, leukemia, tissue injury, bone marrow failure, and immunodeficiency can 
be identified by the irregular total WBC and its differential count. Similarly, bone 
marrow fibrosis, lymphoma, aplastic anemia, and lupus erythematous are associated with 
abnormal platelet counts. Excessive bleeding, kidney bleeding, cancer, and mechanical 
trauma can be identified by the red blood cell (RBC) count [1].  
Cell counting in general and the ability to count specific cells would greatly help in 
diagnostics. Currently, flow cytometers are used for this purpose, but they have not been 
able to penetrate in the resource limited settings around the world because of being 
expensive and requiring trained technicians to operate. Over many years, people have 
developed microfluidic devices for cell counting, which could provide a portable and 
economical solution to the problem [2].  
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1.2. Flow Cytometry 
The current standard used in health-care settings to count blood cells is flow cytometry. 
In this technique, cells are labeled with the antibodies raised for the specific antigen 
expressed on the desired cells surfaces.  These antibodies are conjugated with fluorescent 
molecules called fluorophores. When excited by a specific wavelength, the fluorophore is 
excited to a higher energy level. A molecule absorbs a quantum of light, and the valence 
shell electron moves to the higher energy (excited) state.  The electron relaxes back to the 
lower orbit, i.e. the ground state, and releases energy. Absorption occurs only at those 
wavelengths of light whose energy is equivalent to the energy difference in between the 
excited and the ground states. The wavelength at which the fluorophore gets excited is 
called its excitation spectrum [2]. It relaxes to the ground state, emitting radiation. The 
emitted light has a longer wavelength, and thus less energy than the absorbed radiation.   
After labeling the cells, they are made to pass through the flow cell in a single-file 
manner, where the laser excites the fluorophores attached to the antibodies on the cells as 
shown in Figure 1.1. The emitted light is detected by the different photodetectors. By 
detecting the forward scattered light, cells can be differentiated based on their sizes. 
However, by detecting the side scattered light, cells can be differentiated based on their 
internal cell structure and properties. Different emission filters are placed in front of a 
series of photo detectors to detect the specific emission wavelength. By getting the scatter 
plots of forward scatter vs. side scatter and selecting the appropriate gating thresholds, 
the cells are counted [3]. 
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Figure 1.1: Internal schematic of the flow cytometer. The fluorophores on cells gets 
excited by the laser, and emitted radiation is detected by photodetectors. Adapted from 
[3]. 
Although the flow cytometer gives accurate results, it is still not suitable for point-of-care 
applications in resource-limited regions of the world like sub-Saharan Africa due to the 
following reasons [2]: 
• The equipment is very expensive. The price varies from $50k to over $125k [4]. 
• Maintenance costs around $10k annually [4]. 
• The equipment is bulky (>50lbs). 
• Trained technicians are required to operate this equipment  
This clearly shows the need to have a portable, economical, and robust device for cell 
counting in resource poor regions. 
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1.3. Hematology Analyzer versus Flow Cytometer 
Complete blood cell count (CBC) is one of the most common blood tests referred in the 
hospitals. It includes counting total white blood cells, five-part differential (lymphocytes, 
monocytes, neutrophils, basophils, eosinophils), red blood cells, platelets and their 
indices (mean cell volume), and hemoglobin concentration. The CBC is done on 
automated blood cell analyzers called hematology analyzers. However, for any specific 
cell counting, e.g. CD4+ T cells or CD8+ T cells for AIDS diagnostics or HIV 
management, flow cytometers are used.  
Hematology analyzers are both optical and electrical. In the machine, first the infused 
blood is split into two channels. The blood is lysed in the white blood cell counting 
channel. In optical analyzers, a laser illuminates the cells as they pass through the flow 
cell in a single file manner. The scattered light is collected by two photo-detectors. The 
scattered light collected by the photo detector in line with the laser is called forward 
scatter. However, the scattered light collected by the photo detector perpendicular to the 
laser is called backscatter. Forward scattered light determines the size of the cells and 
backscatter gives the membrane properties information. The forward and backscatter 
plots allow us to differentiate total white blood cells and their sub-types. However, for 
electrical hematology analyzers blood cell counting is also based on the cell size and 
membrane properties, which are probed by using kHz and MHz range frequencies 
respectively given to the electrodes.  
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1.4. Coulter Counting Principle 
The Coulter counting principle was first presented by Wallace H. Coulter and was 
patented in 1953 [5]. Figure 1.2 shows how the Coulter counter works [6]. The chamber 
is filled with electrolytic solution. The metal electrodes are excited with a DC voltage. 
The particles/cells are made to pass one at a time through the small sensing aperture. 
While passing through that aperture the cells displace the electrolytic solution equal to 
their volume and increase the impedance of that region [2]. The aperture is made smaller 
to restrict the electric field for better sensitivity. The change in the impedance is given by 
the Equation 1.1. 
 
Figure 1.2: Coulter counting working principle. The passage of the non-conducting 
particle through the small aperture increases the impedance of the aperture cross-section 
[6]. 
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where Ac is the aperture cross-section, rp is the radius of the particle and ρsol is the 
conductivity of the solution [7]. With the increase in the size of the particle and reduced 
aperture cross-section, the change in the impedance is higher.  
If the particle is more conductive than the electrolytic solution, the impedance 
decreases, but if it is less conductive, the impedance increases. With the increase in the 
impedance, the current drops and downward pulses are obtained as the cells pass through 
the aperture. The depth of the pulse depends on the size of the particle; bigger particles 
displace more conductive solution and thus increase the impedance even more. For each 
passage of the cell, a pulse is produced. Thus, by counting all the pulses, one can find the 
concentration of the particles. And by determining the depth of the pulses the different 
size distributions of the particles can be isolated [2].  
1.4.1. Effect of the coincident particles 
For accurate counting of the cells, no two particles should pass through the aperture at 
one time. As shown in Figure 1.3(a), if two particles are widely spaced enough that for 
each passage of a cell a single unique pulse is obtained, then the particles can be 
accurately counted [6]. However if two particles are sufficiently close together they can 
pass through the aperture at the same time as shown in Figure 1.3(b). Enhanced signal 
processing techniques are required to distinguish such pulses. If two particles are 
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combined together as shown in Figure 1.3(c), they are together represented as a bigger 
size particle, resulting in a higher impedance of the aperture and resulting in a single 
pulse with a higher peak, thus counting as one particle of bigger size [2].     
 
Figure 1.3: Effect of coincidence on particle detection and counting. Adapted from [6]. 
1.5. Electrical Counting of Cells 
Cells respond differently to the application of the electric field. The response depends on 
the amplitude and frequency of the input signals.  
1.5.1. Transmembrane voltage of a cell 
Figure 1.4 shows the cell membrane and its intracellular and extracellular environment 
[8]. The plasma membrane of the cell is made up of a lipid bilayer which consists of 
phospholipid molecules whose heads are hydrophilic and tails are fatty acid chains 
(hydrophobic). When placed in aqueous medium, they form a lipid bilayer membrane [2].  
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Figure 1.4: The cell membrane with its intracellular and extra cellular environment. The 
arrow shows the transport of K+ ions through the ion channel [8]. 
The cell membrane is highly permeable to the water molecules. However, it is 
highly resistive to any transfer of ions across the cell membrane. The concentration of the 
K+ ions inside the cell is higher as compared to outside. The concentration of the Na+ 
ions is lower inside than outside. The transfer of ions is only possible by activating the 
transmembrane proteins called ion channels. The concentration gradient of the K+ ions 
provides the necessary potential energy to activate the K+ ion channel that results in 
transfer of ions from intracellular to extracellular. This results in the negative charge 
inside the cell membrane and induces the positive charge outside the cell membrane. This 
potential difference across the cell membrane is called the transmembrane potential and 
its typical value lies from -40 to -70 mV [2]. 
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1.5.2. Electrical model of a cell 
 Figure 1.5 shows the electrical model of the cell [9]. Rs and Cs are the capacitance and 
resistance of the fluid surrounding the cell. Rc1 and Rc3 are the resistances of the plasma 
membrane (100MΩ), which is highly resistive to the flow of charges. Cm1 and Cm2 are the 
capacitances of the plasma membrane [2]. Rc2 is the resistance of the cytoplasm that 
comes in contact with the nucleus with nucleoplasm resistance, Rm. The capacitance of 
the nuclear membrane is represented by Cn1 and Cn2 and is approximately half of the 
membrane capacitance, since it is composed to two lipid bilayers [9].   
 
Figure 1.5: The equivalent electrical model of a cell suspended in the fluid [9]. 
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Figure 1.6: The voltage across the cell membrane with varying frequency [9]. 
Figure 1.6 shows the frequency response across the outer cell membrane. At low 
frequencies the input voltage appears at the plasma membrane, due to the plasma 
membrane resistance. At frequencies lower than about 100 kHz, the impedance change is 
based on the cell size, since at these frequencies cells behave as a non-conducting fluid 
[10]. At frequencies greater than 1 MHz, the change in impedance is based on different 
structural properties of the plasma membrane. At frequencies higher than 100MHz, the 
change in impedance is based on the nuclear membrane properties as shown in Figure 
1.7. Thus, cells can be differentiated based on their sizes, plasma membrane and nuclear 
membrane structures [2].  
Figure 1.8 shows the passage of the cell in a microfluidic channel and its 
equivalent electrical model.  Below characteristic frequency of 1 MHz the impedance 
change is dependent on the cell size; however, at higher frequencies of greater than 1 
MHz, the change in signal is dependent on the membrane characteristics. At further 
higher frequencies cytoplasm resistance plays the differentiation role [2].  
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Figure 1.7: The potential drop across the plasma membrane (thin line) and nuclear 
membrane (thick line) with varying frequency [10]. 
 
Figure1.8: (a) The equivalent model of a cell when placed in conducting fluid. (b) 
Simulated impedance change with varying frequency [11]. 
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Figure 1.9: The simulated impedance change with frequency for different cell types. At 
lower frequencies the cells can be differentiated based on size, and at high frequencies 
around 1 MHz, the cells can be differentiated based on plasma membrane characteristics 
[11]. 
	   Figure 1.9 shows the simulation results of the impedance change. At frequencies 
of 100 kHz the lymphocytes can be distinguished from monocytes and neutrophils based 
on their size [11]. However, at higher frequencies of greater than 1 MHz the monocytes 
and neutrophils can also be differentiated from each other, as neutrophils have more 
folded membranes [2].  
1.5.3. Electrical double layer capacitance 
For a negatively charged electrode immersed in electrolytic solution, the partial positive 
H of the water molecule gets adsorbed onto the surface forming the first layer, called the 
stern layer. The second layer is composed of free ions attracted towards the stern layer by 
the Coulomb force; however, they are not anchored and can move freely because of 
thermal motion and electrostatic attraction [2]. This layer is called the “diffuse layer” as 
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shown in Figure 1.10. Electric potential at the surface with respect to the bulk fluid is 
called the “electric surface potential” [12].  
 
Figure 1.10: The formation of electrical double layer. The Debye length decreases with 
the increase in the distance from the interface [13].  
The characteristic thickness of the double layer is referred to as the Debye length, 
which is inversely proportional to the square root of the ion concentration. In aqueous 
media its typical value is of the order of few nanometers [2].  
1.6. Forces on a Particle in a Microfluidic Flow 
A cell flowing in a microfluidic channel with electrodes experiences different forces, 
which are depicted in Figure 1.11. 
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Figure 1.11: Effect of the different forces on the particle flowing in the fluid in the 
presence of electric field from interdigitated electrodes. 
1. Sedimentation Force 
Sedimentation is the tendency of the particle to settle down in the fluid.  It 
depends on the value of g, the difference in conductivity between particle and 
medium, and the size of the particle [2]. For smaller sized particles, e.g. cells, this 
force is negligible [13]. It is given by Equation 1.2.  
( )343sedi p mF R gπ ρ ρ= −                        (1.2) 
2. Hydrodynamic Drag Force  
Particles suspended in the fluid experience a hydrodynamic force that depends on 
the relative velocity of the fluid with respect to the particle, co-efficient of 
viscosity and size of the particle [14]. It is given by Equation 1.3. 
( )6HD Drag m pF kRπ η υ υ− ≈ −              (1.3) 
For assuming a parabolic laminar flow profile [2], 
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where U is flow rate in µL/min. 
3. Hydrodynamic lifting force  
Hydrodynamic lifting force tries to lift the particle in the suspension fluid and 
depends on the square of the size of the particle and co-efficient of viscosity. It is 
two orders of magnitude smaller than the typical DEP lifting force and can be 
easily neglected [14]. 
( )
2
0
10.153 |mHD lift xdF R x R dx
υη− =≈ −
                             (1.6) 
4. Dielectrophoresis 
A polarizable particle in the presence of a non-uniform electric field polarizes, 
and a force is produced, known as dielectrophoresis as shown in Figure 1.12. The 
non-uniform electric field exerts a force upon each end of the polarized particle; 
the mobility of the particle and its direction are determined by the difference in 
the magnitude of the two forces on each end [15]. DEP affects neutral particles 
and works for both DC and AC excitation. Positive DEP, movement of the 
particle in the direction of increasing electric field strength, occurs when the 
permittivity of the particle (εp) is greater than that of the medium (εm). Negative 
DEP occurs when εp < εm.  
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Figure 1.12: A polarizable particle in the presence of a point–plane electrode system. 
With application of electric field, the particle polarizes, and a force is produced. This 
effect is known as dielectrophoresis [16]. 
 
The DEP force depends on the size of the particle, permittivity of the particle (εp), 
permittivity of the medium (εm), electric field strength, and real part of the 
Clausius-Mossoti factor fcm. DEP force can be expressed by Equation 1.7. 
3 2
02 Re[ ] | |m cm RMSF r f Eπε ε= ∇        (1.7) 
The Clausius-Mossoti factor fcm is 
( ), 2
p m
CM p m
p m
f
ε ε
ε ε
ε ε
−
=
+
        (1.8) 
The permittivity of the particle and the medium in Equations 1.7 and 1.8 are 
complex permittivity, which is a function of frequency:  
( )pε ε ω=           (1.9) 
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CHAPTER 2 
MICROFLUIDIC IMPEDANCE 
CYTOMETER 
2.1. Introduction  
Label-free cell enumeration in microfluidic biosensors requires counting all cells 
electrically. Individual cell counting in microfluidic impedance cytometers requires a 
Coulter aperture with microfabricated electrodes bonded to it. Cell enumeration in 
microfluidic devices is shown by many studies to count leukocytes and their differential, 
and platelets and erythrocytes. A microfluidic impedance cytometer can provide a point-
of-care device solution for cell counting in resource-limited settings. Such a device can 
work with a finger prick of blood. The key criteria of a point-of-care cell counter include 
the following [2]: 
• It should use the minimum number and amount of reagents for the whole assay, 
which effectively makes the procedure more economical. 
• The device should take whole blood as input, eliminating the need for off-chip 
sample preparation and effectively reducing the assay time as well.  
• The device should be economical for resource-limited settings. The cost per test 
should be reduced to $10 or less. 
• The total assay time should be around 10-15 minutes or less. 
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2.2. Composition of Human Blood 
Human blood is 55% plasma [17] and 45% platelets, white blood cells (also called 
leukocytes) and red blood cells (erythrocytes) as shown in Table 2.1. In each microliter of 
blood, there are almost 5 million erythrocytes and only 7500 leukocytes. Table 2.1 shows 
the different types of the blood cells, their properties and functions. For specific white 
blood cell count, e.g. CD4+ T lymphocytes or monocytes, the challenge lies in counting 
these few thousand cells out of millions of total cells. 
2.3. Experimental Approach 
The experimental flow of our cell counter is shown in Figure 2.1. The whole blood is 
infused on the chip where erythrocytes get lysed and then the white blood cells are 
counted using the microfabricated electrodes [18]. 
 
Figure 2.1: The process flow for the cell counting. 
Figure 2.2 shows the schematic for cell counting process with our biochip. Whole blood 
(10µL) is infused into one port of the device while from the other port the lysing reagent 
composed of saponin (0.05% (w/v)) and formic acid (0.12% (v/v)) in DI solution is 
introduced. This solution makes the surrounding medium for erythrocytes more 
hypotonic, thereby increasing the net inward osmotic pressure difference, resulting in 
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lysing of the red blood cells. The lysing time was optimized to completely lyse all the 
erythrocytes.  
Table 2.1: The different types of cells found in blood with their functions, concentration 
and size. 
Cell Type Function Concentration 
#/µL 
Size 
(Diameter) µm 
Erythrocytes  O2 and CO2 transport 5x106 6-8 
Platelets Blood clotting  3x105 2-3 
Leukocytes  Immune defense 4-11x103 7-21 
Neutrophils Kill invading bacteria 5x103 10-12 
Eosinophils Modulate allergic inflammatory 
responses 
2x102 10-12 
Basophils Histamine release for immune 
responses 
4x101 12-15 
Monocytes  Differentiate into dendritic cells  4x102 14-17 
Lymphocytes  3x103 7-8 
B Cells Make antibodies 2x103 7-8 
T cells Kill virus infected cells and 
regulate other leukocyte 
activities 
1x103 7-8 
Natural Killer 
cells 
Kill virus infected and some 
tumor cells 
1x102 7-8 
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The quenching buffer is then infused from the third port and is composed of sodium 
carbonate and PBS. The main objective of this solution is to halt the lysing process and 
maintain the pH of the solution [18]. The remaining leukocytes pass through the set of 
microfabricated electrodes that count all the passing cells and provide the cell counts. By 
probing the cells at different frequencies, the different types of white blood cells can be 
differentiated based on their size, and cell membrane morphology [2].  
 
Figure 2.2: (a) The schematic of the cell counting approach. The whole blood is lysed 
with lysing buffer and then the quenching buffer is infused to halt the lysing and maintain 
the osmolarity. (b) The schematic of the device showing the ports where samples are 
infused. Lysing region, quenching region, and electrodes are also represented [2]. 
2.4 Erythrocyte Lysing and Quenching Optimization 
The blood sample was focused by lysis buffer sheaths (Figure 2.3a). Erythrocytes were 
ruptured as they flowed through serpentine mixing channels. After completing the lysing 
and quenching processes, the recovered leukocytes could be seen flowing through the 
device (Figure 2.3c) [19]. The recovered cells were collected, tagged with CD45 
fluorescent antibody, and the sample was run through flow cytometer to confirm the 
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presence of leukocytes. The optimal erythrocyte lysis duration is crucial, as it needs to be 
long enough to rupture all the erythrocyte membranes, but short enough to preserve the 
remaining leukocytes. This window was found by locking the flow ratio between blood 
and lysis solution at 1:12 (v/v) and varying the total flow rate to give different resident 
times in the lysing region before lysis was halted in the quenching region [20].  
Figure 2.3d illustrates how on-chip lysis duration affected the population 
distribution of the leukocytes. Each scatter plot compares the low-frequency (303 kHz) 
impedance magnitude, |Z|, to the opacity—the ratio of the high-frequency impedance at 
1.7 MHz to the low-frequency impedance—for a particular lysis time [19]. The low-
frequency impedance level is proportional to size of a cell, whereas the electrical opacity 
gives information about a cell's membrane that is independent of cell size [11, 21-23]. As 
lysis time increased, a portion of the granulocyte/monocyte population transitioned from 
its original population (at 2 s—the optimal lysis time) to between the lymphocytes and 
granulocytes/monocytes population (at 6 s) to its final position, which partially overlaps 
the smaller-sized portion of the lymphocyte population (at 8–10 s). Eventually, 
membranes became fully permeabilized, forming the third population of cells at 10 
seconds (Figure 2.3d) [19]. At 303 kHz, the permeabilized cells cannot be represented as 
non-conducting particles anymore, as electrical conduction takes place through the cell, 
resulting in smaller impedance at 303 kHz (a 64% decrease between the 
granulocytes/monocyte population and the permeabilized population at 10 seconds). The 
1.7-MHz impedance also decreased (42%) for similar reasons, but not to the same extent 
as at 303 kHz—which explains the 63% increase in the permeabilized population’s 
opacity as the high-frequency impedance would already be electrically interrogating the 
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unpermeabilized cells' interiors [20]. To ensure the accuracy of the electrical counting 
procedure, the electrical counts were compared with the counts from the flow cytometer 
(Figure 2.3e). We calculated an R2 value of 0.96, validating the electrical counting 
measurement procedure [19]. 
 
Figure 2.3: Effects of lysis time on erythrocytes and leukocytes. (a) Focusing of the blood 
sample by lysis buffer sheaths. (b) Rupturing of erythrocytes as they flow through the 
serpentine mixing channels. (c) Leukocytes recovered after quenching the lysis process. 
Four of the eighteen leukocytes seen in this panel are encircled (in red). Scale bars (a to 
c), 400 µm. (d) Effects of lysis time on leukocytes. Low-frequency impedance (303 kHz) 
vs. opacity (|Z| @ 1.7 MHz / |Z| @ 303 kHz) scatter plots showing the effect of lysing 
duration on the granulocyte/monocyte population. The arrows illustrate the movement of 
the permeabilized population as the lysis duration increases from 2 to 10 s. (e) Electrical 
chip leukocyte counts vs. the optical counts obtained from Guava flow cytometer (n = 10 
samples), with the solid line representing the best linear fit [19]. 
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 Experiments were also performed to find the minimum quench duration needed to 
create a debris-free leukocyte solution. Quenching times of 7.5 s and 11.3 s did not allow 
the saponin to completely disassociate the erythrocyte fragments or ‘ghosts’ that were 
created from the exposure to formic acid [20, 21]. These fragments still create an 
appreciable change in impedance when they pass through the counter, resulting in a 
baseline noise level that masks many leukocytes. The low-frequency impedance pulse 
histograms in Figure 2.4a show that the erythrocyte debris dominated all counts at 7.5 
and 11.3 s. Complete erythrocyte lysis and debris removal occurred between 11.3 s and 
15.4 s, as the pulse signal-to-noise ratio of about 21.8 was similar to that found by 
analyzing leukocyte populations that were prepared using off-chip techniques, which 
includes lysing, quenching, and washing twice via centrifuge. In addition, the baseline 
root-mean-square (RMS) noise of 28 mV at 15.4 s was similar to that found for the 48.3 s 
quench duration (Figure 2.4a). However, the erythrocyte debris peak at 15.4 s was 
completely removed at 48.3 s, which was confirmed visually by micrographs (Figure 
2.4b); therefore, the minimum quenching time should be approximately 48 s to ensure 
that all erythrocyte debris is removed, ensuring adequate separation from the electrical 
noise and that no debris is falsely counted as leukocytes [19, 20].  
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Figure 2.4: Effects of quenching time on erythrocyte debris [19]. (a) Impedance signals 
and resultant pulse height histograms for various quenching times of whole blood 
samples. Histograms were created by analyzing impedance data using a threshold level of 
0.22 V. The impedance plots are 200-ms snapshots of the electrical data analyzed to 
create their respective histograms. Impedance pulse plots were plotted at the same scale 
for pulse height and baseline noise comparison. (b) Micrographs of the counting channel 
at different quenching times of whole blood samples. Erythrocyte debris is noticeable for 
7.5 s and is absent at 48.3 s. Flow direction is from left to right in all micrographs. 
Arrows signify the position of leukocytes along the channel. Scale bars, 200 µm.  
 
 
25	  
	  
2.5. Electrical Counting of Cells 
Much progress has been made in impedance micro-cytometry with alternating current 
interrogation to detect differences in chemically modified cells [21], to evaluate cellular 
processes [24], and discriminate among cell types [25, 26]. The technique still has not 
proven to be sensitive enough to distinguish among cells that have similar morphologies, 
such as CD4+ T lymphocytes and other lymphocytes.  
Figure 2.5(a) shows the microfabricated electrodes. The yellow arrows show the 
typical cells passing through the chamber. The counting channel has a cross-section of 15 
x 15µm2 which facilitates the signal strength [19]. For each passage of the cell, the 
electrodes generate a bipolar pulse as shown in the enlarged version of Figure 2.5(b). At 
the counter, all these pulses are counted to obtain the total count by selecting the 
appropriate threshold. 
 
Figure 2.5: (a) Microfabricated electrodes. The yellow arrows show the typical cells 
flowing. (b) The pulses it generates with the passage of the cells [19]. 
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2.5.1. Analysis of counts 
The lock-in amplifier injects 303 kHz and 1.7 MHz signal to the middle counting 
electrode. Relative impedance is measured by a Wheatstone bridge circuit. At low 
frequencies like 303 kHz, the leukocytes can be differentiated based on the cell size. At 
this frequency, the cells act as non-conducting spheres and completely block the 
electrical current when they displace the conductive fluid which depends on the size/ 
volume of the cell. The histogram at 303 kHz is shown in Figure 2.6(a) in which 
lymphocytes are easily distinguishable from monocytes and granulocytes. At high 
frequencies around 1.7 MHz, the measured impedance depends upon the cell membrane 
capacitance and cell morphology. For example, monocytes have higher cell membrane 
capacitance and have extensive folding in the membrane as compared to neutrophils, so 
they can be differentiated. Thus, by probing the cells at these frequencies we can 
differentiate between erythrocytes debris and different types of leukocytes like 
lymphocytes with granulocytes and monocytes. Figure 2.6(b) shows the scatter plot of 
opacity (which is the impedance change due to high frequency divided by the impedance 
change due to low frequency) versus the impedance change at low frequency (303 kHz). 
As shown in the figure, we can easily distinguish the red blood cells debris, and the two 
cell distributions show the differentiation between lymphocytes and granulocytes [19]. 
The dashed rectangular gates are drawn and cells enclosed in the gates were counted as 
forward and reverse counts respectively.   
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Figure 2.6: The low-frequency histogram distribution [19]. (b) The opacity vs. low-
frequency scatter plot. Lymphocytes can easily be differentiated from monocytes and 
granulocytes [19]. A gating technique was used to determine the total leukocyte and 
lymphocyte counts.   
2.5.2. Gating strategy for cell counting 
 We used a gating strategy similar to standard flow cytometry methods to quantify the 
captured lymphocytes.  Figure 2.6b shows a typical example of gating, which is always 
performed on the low-frequency impedance vs. opacity (high-frequency impedance/low-
frequency impedance) plots.  The distribution at the left (Figure 2.6b, red box) represents 
the lymphocytes. This red gate representing lymphocytes was drawn between two 
minimum density values (one between debris and lymphocytes population, and other 
between lymphocytes and granulocytes/monocytes population). The number of captured 
lymphocytes, i.e. the target CD4+ T cells, was calculated by subtracting these gated 
distributions of the exit count from the entrance count [19].  
2.5.3. Electrical cell pulse selection 
After the lysing of the erythrocytes, the remaining leukocytes pass through the electrodes 
and generate a bipolar pulse during the passage of each cell. The bipolar pulse obtained 
from the differential signal V1-V2 can also be used for cell counting, with each bipolar 
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pulse representing a cell. Figure 2.7a shows the bipolar pulse generated for a typical 
lymphocyte (with an average radius of 3.9 µm). However, Figure 2.7b shows the higher 
amplitude bipolar pulse generated for granulocytes or monocytes, which have a larger 
size with an average radius of 4.7 µm. The histogram in Figure 2.7c represents the pulse 
count at different pulse amplitudes and shows the two distinct distributions for 
lymphocyte and granulocyte/monocyte population. The number of the cells can be 
counted by either selecting the positive or the negative pulse. The threshold value, Th., as 
shown in Figure 2.7c, indicated by the black arrow, is the voltage amplitude value used 
for cell counting [27]. The threshold value is selected by considering the minima in 
between lymphocyte distribution and debris. Figure 2.7c shows the histogram obtained 
for the negative pulse. The positive pulse is of higher magnitude as compared to the 
negative pulse, and the difference can be observed from Figure 2.7(a,b). This difference 
is also clear from the shift in the histogram as indicated by the arrows i and ii, which 
represent the peak amplitude value for lymphocytes and granulocytes/monocytes 
distributions, respectively. The peak amplitude values of [i, ii] obtained for negative 
pulse is [0.3 0.7] V and for positive pulse is [0.45 0.95] V [27]. This difference in 
amplitudes should be considered while selecting the threshold value for cell counting 
either from the positive or the negative pulse.  
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Figure 2.7: The threshold selection for the cell counting method [27]. (a) A typical 
bipolar pulse for the lymphocyte. (b) A typical bipolar pulse for the 
granulocyte/monocyte. As is clear from these bipolar pulses, the upward pulse is of 
higher magnitude than the downward pulse, showing the cell moves downward as it 
moves along the measurement channel. (c) The histogram showing the two distributions 
of lymphocytes and granulocytes/monocytes by analyzing the negative pulse. (d) The 
histogram showing the two distributions of lymphocytes and granulocytes/monocytes by 
analyzing the positive pulse. The voltage shift in amplitude is about 0.2 V. The peak 
amplitude of the lymphocyte and granulocyte/monocyte distribution represented as [i ii] 
for negative pulse is [0.3 0.7] and for positive pulse is [0.45 0.95].  
2.6. Electrical and Optical Cell Counts Comparison  
To check the accuracy of the electrical counting procedure, the electrical counts are 
compared with the optical counts. After the lysing, quenching and forward counting of 
the blood, the sample is collected into the tube filled with 1200µL of PBS+1%BSA, and 
then it is centrifuged for 5 min at 300rcf; supernatant is poured out and the cell pallet is 
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further mixed in 600µL of PBS+1%BSA. This sample is run through a flow cytometer to 
count the total number of cells present [19]. Figure 2.8 shows a high correlation, with an 
R2 value of 0.9584, between total forward count from the chip and the optical count from 
the flow cytometer, thus proving the validity of the electrical counting measurement 
procedure [19].  
 
Figure 2.8: The comparison of the electrical chip counts vs. the optical counts obtained 
from flow cytometer. The R2 value of 0.9584 shows the accuracy of the electrical 
counting method [19]. 
2.7. Cell Viability Analysis 
In a single counter case, the leukocytes were exposed to lysing and quenching reagents 
for almost 30 min for the flow rate of 20 µl/min. This exposure time is mainly the time 
the cells remained exposed to the reagents before the flow is reversed and cells are 
counted again. For the characterization of the dual counter situation, the entrance and exit 
counters were connected with the microbe PTFE tubing of internal diameter of 0.15 mm; 
to achieve a 15-µl volume of the capture chamber, an equivalent tubing length of 85 cm 
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was used. The tube simply simulates a chamber with no capture so that the cells are not 
lost due to capture; rather, any loss would be attributed to the exposure to the lysing and 
quenching solution. This results in the exposure of cells to lysing and quenching reagents 
for less than a minute, and in turn helps in maintaining the cell viability.  
We also investigated the effects of lysing and quenching reagents on the cell 
viability. For a single counter case, the flow is reversed for the exit count and cells were 
exposed to reagents for varying times depending on flow rate (Table 2.2). We observed a 
difference of almost 20% cell loss between forward and reverse counts. However, when 
two counters were used—one at the entrance and other at the exit of the capture 
chamber—exposure to the reagents was reduced to less than 1 minute (Table 2.2), which 
resulted in < 1% cell loss (Figure 2.9).  
Table 2.2: Time exposure of the lysing and quenching buffers in single and dual counter 
case at different flow rates [19].  
 Single counter Dual counter 
Flow 
rate 
(µl/min) 
Experiment 
time (min) 
Exposure to lysing 
+ quenching 
buffer (min) 
Experiment 
time (min) 
Exposure to 
lysing + 
quenching buffer 
(min) 
20 45 30 20 0.75 
30 35 25 15 0.5 
40 30 22.5 13 0.375 
50 23 17 10 0.3 
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Figure 2.9: The percent cell counting error for a single vs. dual counter approach [19].  
2.8. Volumetric Flow Metering 
Integrated flow metering is essential in lab-on-chip and microfluidic devices. The 
impedance across the electrodes increases as the cells pass through the channel. The 
change in the impedance also depends on the flow rate at which the fluid is flowing, thus 
providing an opportunity to meter the fluid volume. Errors in fluid volume can come 
from the variance in the device channel dimensions, introduction of bubbles, or fluid 
dead volumes. This could become a significant problem for a single blood drop point-of-
care devices as only a few microliters of blood are used in these measurements [27, 28].   
The flow of electrolyte in a microfluidic channel is given by a parabolic profile when the 
flow is laminar (Reynolds number < 1) and would result in the redistribution of ions 
within the electric double layer in the channel [29-31]. When the AC voltage is applied 
across the channel electrodes, the ions respond to the electrical fields across the 
electrodes [32]. The electro-kinetic effects result in ionic redistribution, which then 
results in changing the electrical impedance across the electrodes. Thus, the flow of the 
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fluid in a microchannel can be related to the change in the impedance across the micro 
electrodes [33-35]. The different parameters including the amplitude of AC voltage, the 
frequency of the signal, the conductivity of the electrolyte, and the dimensions of the 
electrodes, need to be optimized for better sensitivity [29, 36]. With increase in the flow 
rate, the mass transport increases due to increase in the ionic concentration. The mass 
transport limited current, iL, increases as it is directly proportional to the cube root of the 
volumetric flow rate, Q of the fluid, as given by Equation 2.1 below [29, 37]. 
               (2.1) 
where n is the number of electrons transferred, F is the Faraday constant, l is the 
electrode length, h is the cell half-height, w is the width of the cell, we is the electrode 
width and DA is the diffusion coefficient [29].  
Using that device design, here we show that we can meter the fluid sample using the 
same electrodes used to count the cells. We have characterized the impedance change and 
the cell counts in the fluid versus different flow rates and show that these parameters can 
be used to meter the solution in the microfluidic devices [27, 28].  
2.8.1. Electronic setup 
The electronic measurement setup for flow characterization is shown in Figure 2.10. Z1 
and Z2 represent the impedance in between the middle and the side electrodes and R is 
the 10 kΩ resistance connected as part of the Wheatstone bridge circuit. The input signal 
of 5V at 303 kHz is fed to the middle electrode. Two different referenced signals are 
collected, first, a differential V1-V2 signal for cell counting using a differential amplifier, 
and second, V1 or V2 voltage signal that is referenced with ground.  The differential 
2/3 1/3 2 230.925 [ ] /L bulk A ei nF A D Q w l h w=
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signal, a bipolar pulse, is generated for each passage of a cell across the electrodes. The 
height of the pulse depends on the size of the cell and the distance from the electrodes, 
whereas the pulse width depends on the flow rate [27]. As we show later, the baseline of 
the signal also depends on the flow rate of the solution and its average value can be used 
to meter the flow rate.  
 
Figure 2.10: Electronic setup for volumetric flow metering characterization [27]. 
2.8.2. Flow characterization with signal baseline shift 
The amplitude change in the baseline of the voltage signal acquired is used for the flow 
metering as shown in Figure 2.11. The flow rate is varied from 10 µL/min to 60 µL/min 
with the increments of 5 µL/min while keeping the flow rate constant for about 120 
seconds, and the change in the baseline amplitude of the ground referenced signal is 
measured. First, the voltage change in baseline is measured by flowing the lysing and 
quenching solutions together, which linearly increases with the increase in the flow rate 
with an R2 value of 0.9882 as shown by blue points in Figure 2.11a. The blood is then 
infused with the lysing and quenching reagents and the change in the baseline shift is 
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recorded with varying flow rates. These results also show a high linear correlation (R2 = 
0.9906) with slightly less amplitude than the former case with only lysing and quenching 
solutions [27]. It should be noted that the flow can also be metered by measuring the 
change in the baseline shift of the differential signal V1-V2, which also increases linearly 
with increasing flow rate with a high correlation (R2 = 0.966) as shown in Figure 2.11b.    
 
Figure 2.11: Flow metering of the lysed blood in the measurement channel. (a) The linear 
relationship between the amplitude increase of the baseline signal obtained (i.e. V2 or V1 
voltage measured with reference to ground) with increase in the flow rate (R2 = 0.9882). 
The change in amplitude by varying flow rate between lysed blood and lysing & 
quenching solutions is not great. The signal amplitude increases stepwise as the flow rate 
is increased (R2 = 0.9906). (b) The linear relationship between the increases in the 
baseline signal (i.e. V1-V2, a differential voltage signal) obtained with an increase in flow 
rate (R2 = 0.9656). Error bars represents one standard deviation across 3 experiments 
[27].   
2.8.3. Flow characterization with cell counting (cell flux) 
With the increase in the flow rate, the number of cells flowing through a measurement 
channel per unit time would also increase. Figure 2.12a shows the linear relationship in 
the increase of the cells flowing per minute with the increase in the flow rate with a high 
correlation of (R2 = 0.9656). However, with increase in the flow rate the number of cells 
present in one microliter of solution would remain constant. In experiments, with varying 
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flow rates, the number of cells/µL passing through a cross-sectional area of electrodes in 
one minute is calculated and is shown in Figure 2.12b. The average number of cells/µL in 
one minute is measured with varying flow rates of 10-60 µL/min and is found to be 47 
with one std. of cells/µL [27]. The number of cells/µL in a unit time should remain 
constant. However there is a variation in number of cells/µL with increasing flow rates as 
shown in Figure 2.12b. This can be attributed to cell counting error within that one 
minute time period, which could be reduced by computing the number of cells/µL for 
higher time intervals.  
	  
Figure 2.12: (a) Linear relationship between the flow rate and the number of cells passing 
through the channel in unit time with high correlation of (R2 = 0.9656). (b) The number 
of cells/µL is the ratio of cells/min: flow rate. This ratio should be constant with varying 
flow rates. For 10-60 µL/min range, the average value of the cells/µL in one minute is 47 
with one. std. = 7 cells/µL. The accuracy is 5.42%. Error bars represents one standard 
deviation across 3 experiments [27].   
2.8.4. Flow characterization with cell pulse width 
The width of the pulses generated as the cells pass through the electrodes depends on 
how fast the cells are flowing. We found that the pulse width is inversely proportional to 
the flow rate; thus, the mean value of the pulse width can also be used to determine the 
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flow rate [27, 28]. Figure 2.13 shows the relationship between the monotonic decrease 
with correlation of R2 = 0.8659 in the pulse width as the flow rate is increased from 10-
60 µL/min. The mean value of the pulse width, once pre-calibrated, can also be used to 
characterize or determine the flow rate of the fluid that the cells were suspended in.  
 
Figure 2.13: The linear relationship between pulse width and varying flow rate. The pulse 
width can also be calibrated and used for flow metering. Error bars represents one 
standard deviation across 3 experiments [27].   
2.8.5. Discussion 
The flow rate characterization of our approach is based on the cell counting applications 
which usually require the flow rates to be around 10-100 µL/min. The dynamic range of 
flow rate in our experiments is 10-60 µL/min. As compared to our approach, the optical 
fiber cantilever based flow characterization gives an ultra-wide dynamic range of 10-1500 
µL/min, with the minimum detectable change in the flow rate being about 31 µL/min for 
DI water [27].  
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The increase in impedance with flow rate depends on the ionic concentration of the 
solution. For different blood samples, the number of erythrocytes varies from 3.26 to 5.99 
million cells per microliter of blood (mean = 4.7 million cells, standard deviation = 0.46 
million cells). This wide range results in different ionic concentrations of the fluid after 
the erythrocyte lysis, thus resulting in different slopes for the linear relationship of 
increase in impedance with increase in flow rate. The slope increases with the increase in 
the hematocrit value of the blood samples. The baseline amplitude difference 
corresponding to the different slopes is less for the lower range of the flow rates. In the 
current experiments, the dynamic range is 10-60 µL/min, and the current calibration 
curve for flow metering would work for all blood samples [27]. However, a new 
calibration curve will be needed if the fluid sample is flowing at much higher rates or if 
we use different concentrations of the lysing/quenching buffers. 
The flow metering based on the change of baseline amplitude shows a high correlation as 
compared to the characterization with pulse amplitude and cell flux. Furthermore, the 
change in the baseline shift of ground referenced signal is much higher (20 times) as 
compared to the change of the baseline amplitude in the differential signal. However, the 
main advantage to determine the flow rate by the pulse width is that it is independent of 
the small changes in the ionic concentration that may arise due to the difference in red 
blood cell concentration in the blood samples [27]. However, the flow metering based on 
the cell flux is more sensitive to the variation of the number of blood cells in different 
samples. The strength of the proposed approach is that by acquiring a single voltage 
differential signal, the baseline amplitude, cell flux and pulse width can all be measured. 
Thus, using a single signal, the flow rate characterization can be done by all techniques.    
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Accuracy in estimating the flow rate with the number of cells passing through the 
counting channel per unit time depends on the cell density in the solution. In healthy 
individuals, on average there are about 6000 leukocytes/µL with standard deviation of 
500-800 cells/µL. This variation in density of cells in the sample could be a source of 
error. For every 5 µL /min change in the flow rate, the mean change of cell flux is about 
220 cells/min. The 10% variation in the blood cell count would produce a change of 
around 30 cells. This would limit the flow rate detection to approximately 2 µL /min [27]. 
However, for all clinical blood cell counting applications there will be much more 
variation in the cell concentration range. Furthermore, for simultaneously performing cell 
counting and flow metering characterization, the cell flux approach cannot be applied 
directly. In such applications, volume will metered by baseline shift or pulse width 
method and cell concentration will be computed, which can be further used to meter the 
volume. 
The amplitude impedance change between positive and negative pulses could result from 
the application of hydrodynamic forces on the cells as they pass through the measurement 
channel, thus changing the position of the cell relative to the electrodes. The high flow 
rates 20-60 µL/min would result in significant drag force greater than the sedimentation 
and the lift force [38, 39]. However, it should also be noted that the fabrication 
inaccuracies between the three electrodes due to small variation in the platinum 
deposition and the electronics might also be the source of error for the variation in the 
impedance amplitude of the pulses. Another possibility is the increase in the 
hydrophobicity of the PDMS devices over time. The oxygen plasma treatment of the 
PDMS results in producing the reactive silanol groups on the surface which reoriented 
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back to the bulk over time during “hydrophobic recovery” [27]. Increase in the 
hydrophobicity also increases the fluid contact angle on the PDMS surface, which might 
create more resistance to the fluid flow and could be a source of error of amplitude 
variation in the pulse. The measurement of this amplitude change is important while 
selecting the threshold value for positive or negative pulse for accurate cell counting and 
in turn flow characterization through cell flux.  
2.9. Experimental Apparatus 
Figure 2.14 shows the experimental setup. An Eksigent Nanoflow LC pump (Dublin, 
CA) is used to infuse the lysing, quenching, and PBS reagents into the chip at desired 
flow rates. A Rheodyne MHP7980-500-1 valve (Rohnert Park, CA) is used to load 10 µL 
of blood sample into a 10 µL holding coil (via syringe) and then direct PBS through the 
coil to inject the blood sample into the chip [19, 20].  
A Zurich Instruments (Zurich, Switzerland) HF2LI lock-in amplifier was used to 
simultaneously inject 303 kHz and 1.7 MHz AC signals of 5V rms into the chip’s center 
counting electrode [19]. Relative impedance was measured by creating a Wheatstone 
bridge circuit with 10 kΩ resistors. The voltage difference between the two Wheatstone 
branches was fed to the differential preamplifier (Zurich Instruments). The signal is then 
fed to the lock-in amplifier and sampled at 250 kHz in LabVIEW on a computer with a 
PCI-6351 DAQ card (National Instruments, Austin, TX). A customized Matlab program 
was developed to count the pulses at the user-desired threshold value [19].  
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Figure 2.14: Schematic of the experimental setup. 
2.10. Device Fabrication 
2.10.1. Electrodes fabrication protocol 
Electrodes were fabricated on a 4 inch Pyrex Glass wafer using the following protocol: 
• Piranha clean (sulfuric acid: hydrogen peroxide, 1:1) for 15 minutes and then 
rinse 10 times.  
• Dehydration bake is performed at 110 °C for 5 minutes minimum with 5 minutes 
cool-off time. 
• LOR 3A is spin-coated for 500 to 3000 rpm in 2 sec and hold for 35 sec.  
4. Soft bake is done at 183 °C for 5 minutes with further 5 minutes cool-off time.  
• S1805 is spin-coated for 500 to 4000 rpm in 3 sec and hold for 40 sec.  
• Soft bake is done for 90 s at 110 °C with 5 minutes cool-off to prevent wafer from 
sticking to mask.  
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• The wafer is exposed for 1.3 seconds; time is calculated based on the exposure 
energy and power output.  
• Post-exposure bake is done for one minute at 110 °C.  
• The wafer is developed in CD-26 for 20 s.  
• Before metal deposition the wafer is cleaned using oxygen plasma for 20 sec.  
• Metal evaporation is done for 250 Å of titanium and 750 Å of platinum. 
• Metal lift-off is done using Remover PG.  
2.10.2. Fluidics mask fabrication 
The multilevel fluidics layer was created using standard rapid microfluidic prototyping 
using Microchem SU-8 negative photoresists and Polydimethylsiloxane (PDMS). A 
negative master was constructed on a 4" Si wafer using four successive iterations of the 
standard SU-8 recipe, with all soft-bake and post-exposure bake durations and 
temperatures being similar to those suggested in the SU-8 product sheets. SU-8 was spun 
to a height of 15 µm and exposed using the EV420 mask aligner to define the counting 
and filter regions and provide a base for the other regions [19]. A 55 µm layer was then 
spun on and exposed to define the 60 µm tall capture region. 30 µm of SU-8 50 was 
deposited to define the 100 µm lysis region, followed by a 50 µm layer to create the 150 
µm quenching region. Development in SU-8 developer was deferred until all four layers 
were created. After development and rinsing the mold with IPA, a 1:10 curing agent to 
base mixture of PDMS was poured over it and cured for at least 15 minutes at 150 °C to 
create the fluidic channels. The fluidic inlets and outlet were cored out of the PDMS 
mold using a custom hole punch [20].  
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CHAPTER 3 
MATHEMATICAL 
CHARACTERIZATION OF ELECTRICAL 
CELL COUNTING PROCESS  
 
3.1. Introduction 
Cell counting in microfluidic chips can be done by passing a particle through a coulter 
aperture with co-planar or top-bottom electrodes bonded to it. Cell counting in a coulter 
counter follows the Poisson statistics. However, its detailed characterization is critical in 
accurate cell counting in microfluidic devices. In high cell concentration samples e.g. in 
erythrocyte counting from diluted whole blood , a portion of the sample is considered for 
cell counting because of high volume of total sample after dilution. In such applications, 
the cell counts assume to follow uniform distribution throughout the experiment. 
However, as we will show in this chapter, the distribution depends on the effectiveness of 
the buffer pushing the sample; with an ineffective buffer, the cells gets diffused into the 
buffer and cell counts do not follow a uniform distribution over time. This makes the 
sample portion selection very critical. Another important parameter to characterize is the 
amount of the dilution required for accurate cell counting as this limits the time, 
throughput, power and the amount of the reagents used in the device.   
Using our cell counting biochip, in this chapter we give a complete characterization of 
the cell counting process.  We have characterized the cell counting process over time as a 
non-homogenous Poisson process and shown that this characterization is useful for buffer 
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characterization, required sample dilution estimation and accurate cell counting [40]. The 
contents of this chapter are taken from our work published as "Electrical cell counting 
process characterization in a microfluidic impedance cytometer," Biomedical 
Microdevices, vol. 16, pp. 697-704, 2014.  
3.2.  Experimental Protocol 
The schematic of the biochip is shown in Figure 3.1. The 10 mL of whole blood is 
infused at one of the three inlet ports (represented by red color). The lysing reagent is 
infused at the yellow port. The mixing of the blood with the lysing buffer in the lysing 
region resulted in complete lysis of erythrocytes. The quenching buffer is infused at the 
blue inlet port to stop the lysing process and maintain the osmolarity and pH of the 
solution [41]. The quenched sample flows through the 15 x 15 mm2 cross-sectional cell 
counting channel with microfabricated electrodes aligned with it. Figure 3.1a also shows 
the typical leukocytes passing through the cell counting channel represented by blue 
circles. As each cell passes through the microfabricated electrodes, it generates a bipolar 
voltage pulse. Figure 3.1b shows the typical voltage signal acquired during the cell 
counting experiment for 2 sec. Many cells pass through the counting channel as seen by 
the many bipolar pulses. Figure 3.1c shows a typical bipolar voltage pulse generated at 
each cell passage.  All the bipolar voltage pulses are recorded above 3 times standard 
deviation of noise and a pulse amplitude histogram is plotted as shown in Figure 3.1d. 
The dotted rectangular region shows the two leukocyte populations including 
lymphocytes and granulocytes + monocytes. The left population in the dotted rectangle 
represents the lymphocyte population as they are smaller in size with almost 7.8 mm 
average diameter as compared to granulocytes + monocytes with almost 12 mm average 
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cell diameter.  The left region to the dotted rectangular is erythrocyte debris and the 
rectangular leukocyte region is selected by considering the minima in between the debris 
and lymphocyte population.  
	  
Figure 3.1: Experimental Setup [40]. (a) The device layout with lysing and quenching 
modules is shown. Blood, lysing and quenching solutions are represented by different 
colors at their respective infusion ports.  The “Lysing” indicates the region where blood 
and lysing buffer mixed to lyse all erythrocytes. The “Quenching” indicates the region 
where quenching buffer gets mixed to maintain the osmolarity of the solution. The 
zoomed-in version of yellow electrodes shows the cell counting region of 15x15 um2 
cross-section with electrodes aligned with it. The blue circles show the typical leukocytes 
passing through the measurement channel. (b) The bipolar pulses for each passage of a 
cell (c) A typical bipolar voltage pulse.  (d) The pulse amplitude histogram is plotted. The 
dotted rectangular region shows the two leukocyte populations including lymphocytes 
and granulocytes + monocytes.  
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3.3. Cell Diffusion Characterization  
The electrical cell counts are obtained for the entire experiment duration of 15 minutes. 
The entire duration is divided into 100 time intervals and a histogram is plotted for the 
cell counts w.r.t experiment time and is shown in Figure 3.2a [40]. Cell count distribution 
over time shows the log-normal function with characteristic value of µ = 1.644 and σ = 
0.3728. It is given by Equation 3.1.     
𝑦 = 𝑓 𝑡     𝜇,𝜎) =    !!" !! 𝑒! !" !  –  ! !!!! 	  	  	  	  	  	  	  	  	   	   	   	   	   	   	  	  	  	  (3.1)	  
The log-normal cell counting distribution can be explained by the cell diffusion in the 
buffer as shown in the conceptual illustration in Figure 3.2b. The cell counts over the 
experiment duration were expected to follow a uniform distribution. However, we see a 
very rapid increase in the cell counts during the start of the experiment and a slow 
decrease in the cell counts at the end of the experiment. The ‘buffer’ in Figure 3.2b 
represents both lysing and quenching solutions together. Before the blood starts to flow in 
the bio-chip, a buffer is already flowing in the bio-chip [40]. The buffer solution interacts 
with the blood allowing the cells to diffuse and allowing some cells to appear early. The 
mass transfer coefficient given by 𝑘 =   𝐷/𝛿 depends on diffusion coefficient, D, and 
depth of diffusion layer, δ  [42]. The mass transfer coefficient at the start of the 
experiment 𝑘! is lower than its value at the end of the experiment 𝑘!, as the depth of the 
diffusion layer is greater at the start. This in turn results in higher rate of flow of cells to 
the buffer, 𝑣! at the end of the blood infusion [40]. Mathematically this can be written as, 
𝑣! = 𝑘𝐴  ( 𝑀𝑜𝑙!"##$ − [𝑀𝑜𝑙!"##$%])	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3.2)	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where A is the cross-sectional area of the channel, [𝑀𝑜𝑙!"##$] is the number of cells in 
blood and [𝑀𝑜𝑙!"##$%] is the number of cells in the buffer after diffusion [40]. 	  
	  
Figure 3.2: (a) Histogram representing the electrical cell counts throughout the entire 
experiment time. The histogram shows the log-normal function (µ = 1.644 and σ = 
0.3728). (b) Conceptual illustration of the log-normal cell distribution. The buffer 
interacts with the blood at start and end of blood infusion and results in diffusion of cells 
[40].  
3.3.1. Diffusion characterization with heterogeneous cell population 
The mean value of the log-normal distribution, µ, of cell counts decreases with the 
increase in the flow rate with an R2 value of 0.96 as shown in Figure 3.3a.  This decrease 
can be associated with the decrease in the total experiment time as the flow rate is 
increased while using the same volume of blood sample, i.e. 10 µL.  Figure 3.3b shows 
the histogram of the lymphocytes and granulocytes + monocytes cell counts over the 
experiment duration. The diffusion coefficient 𝐷 =    !"!!"# depends of the size of the 
particles/cells. Lymphocytes, being smaller, have a higher diffusion coefficient of 41.40 
fm2/sec as compared to granulocytes + monocytes with a value of 26.91 fm2/sec. The 
higher diffusion coefficient,  𝐷 for lymphocytes results in higher value of mass transfer 
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coefficient  𝑘, which in turn increases the rate of flow of lymphocytes to the buffer  𝑣 as 
compared to granulocytes + monocytes [40]. This results in a more skewed distribution 
for the lymphocytes as compared to granulocytes + monocytes as shown in Figure 3.3b. 
The µ value of the log-normal distribution decreases linearly with the increase in the flow 
rate for lymphocytes with an R2 value of 0.92 and granulocytes + monocytes with an R2 
value of 0.98 as shown in Figure 3.3c.  This decrease can be associated with the decrease 
in the total experiment time as the flow rate is increased while using the same sample 
volume. The skewness of the log-normal function written in Equation 3.1 is given 
as  (𝑒!! + 2) (𝑒!! − 1), and gives a high value for lymphocytes as they get diffused 
more as compared to granulocytes + monocytes [40]. Figure 3.3d plots the skewness of 
the log-normal distribution for leukocytes, lymphocytes and granulocytes + monocytes. 
The skewness decreases linearly with increasing flow rates for leukocytes, lymphocytes 
and granulocytes + monocytes with an R2 value of 0.94, 0.92, and 0.98 respectively. The 
high skewness for lymphocytes verifies that they get more diffused in the buffer as 
compared to granulocytes + monocytes as shown in Figure 3.3d.   
3.4. Cell Counting Characterization as a Poisson Process 
The cell counting process can be mathematically related to a Poisson process [43]. A 
Poisson process is a stochastic process which counts the number of events and the time of 
each event with respect to each other in a given time interval. Figure 3.4a shows a 
graphical depiction of a Poisson process which shows that the number of the cell counts 
(events) X, in the interval t1 to t2, follows a Poisson distribution with a parameter value λ, 
as given by the following equation [40]. 
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𝑦 = 𝑃(𝑋 = 𝑘) = !!!!!!!                                                                                                                                                                                                                                                             (3.3)  
 
Figure 3.3: (a) The µ value of the log-normal distribution of cell counts decreases with 
the increase in the flow rate as the experiment time is reduced (R2 = 0.96).  Error bars 
represent one standard deviation of the log-normal distribution at each flow rate.  (b) 
Shows the histogram of the lymphocytes and granulocytes + monocytes cell counts over 
the experiment duration. The lymphocytes showed greater skewed distribution as 
compared to granulocytes + monocytes. (c)  Shows the decrease in the µ value of the log-
normal distribution of lymphocytes (R2 = 0.92) and granulocytes + monocytes (R2 = 
0.98) with the increase in the flow rate as the experiment time is reduced.  (d) The 
skewness of the log-normal distribution decreases with increasing flow rates for 
lymphocytes (R2 = 0.94) and granulocytes + monocytes (R2 = 0.98). The lymphocytes 
show higher skewness as compared to granulocytes + monocytes as they get more 
diffused in the buffer [40].  	  
A Poisson process can be subdivided into sub-Poisson processes for different time 
intervals as shown in Figure 3.4b. If the values of λ are same for sub-processes, the entire 
process is a homogenous Poisson process, for different values of λ the process is called a 
non-homogeneous Poisson process [44]. The cell counting process of our experiment is a 
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non-homogenous Poisson process, as the total number of cell counts changes over time 
throughout the experiment as we have shown in Figure 3.2a.  
	  
Figure 3.4: (a) Poisson process describes the number of cell counts in a particular time 
interval. N(t) is the number of counts in the interval 0 to t, and obeys a Poisson 
distribution. (b) A Poisson process can be subdivided into sub-Poisson processes for 
different time intervals, e.g. t1 or t2. If the values of λ are the same for sub-processes, the 
entire process is a homogenous Poisson process; for different values of λ the process is 
called a non-homogeneous Poisson process. The cell counting process is a non-
homogenous Poisson process. (c) The number of cell counts in time interval 5 to 6 sec 
(bins = 200). (d) The Poisson distribution of the cell counts in interval 5-6 sec with a λ 
value of 4 [40].         
The cell counting process for the entire experiment is divided  into sub-processes of one 
minute time interval, which can be represented as Poisson processes as the cell counts 
follows a Poisson distribution in those sub processes [40]. Figure 3.4c shows the number 
of cell counts in a time interval of 5 to 6 minutes which can be approximated as the 
uniform occurrence of cell counts for this entire duration. The 5-6 minute duration is 
divided into 1000 intervals, and the number of cells was calculated in each interval. The 
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corresponding Poisson distribution of the cell counts in the 5-6 minute interval is shown 
in Figure 3.4d with a λ value of 4.         
3.4.1. Cell counting experiment, a non-homogeneous Poisson process 
The cell counting process for the experiment duration is represented as a non-
homogeneous Poisson process by the following mathematical relation: 
(!!!)!!!!"!!   𝑑𝑚!!!!!                                                                                  (3.4) 
where 𝑡! is the total experiment duration in minutes, and 𝑑𝑚 is the time interval for the 
sub-process which follows the Poisson distribution for the cell counts, in our case one 
minute. The λ value is time-dependent as the total number of cell counts differs for 
different times during an experiment as shown in Figure 3.2a. The λ value is calculated 
for duration of one minute throughout the experiment and is shown in Figure 3.5. The λ 
value for lymphocytes is slightly greater than granulocytes + monocytes because of their 
slightly higher concentration in the sample after blood lysing. The λ value can be 
represented as a log-normal function whose µ value depends on the flow rate and the 
sample volume used for the experiment [40].  
3.5. Inter-Cell Spacing Characterization  
The inter-event spacing of the Poisson process should follow the exponential distribution 
as shown in inset of Figure 3.6a. The time difference between the cell occurrences should 
follow the exponential distribution which can be given by the following equation: 
  𝑦 = 𝑓 𝑡 𝜇) = !!   𝑒!!!                                                                                                                                                                                                                                         (3.5)  
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Figure 3.5: The cell counting process for the experiment duration is a non-homogeneous 
Poisson process. The plot represents the λ value for duration of one minute throughout 
the experiment. The λ value for lymphocytes is slightly greater than granulocytes + 
monocytes because of their slightly higher concentration in the sample after blood lysing 
[40].   
The inter-cell spacing of total leukocytes (N = 18599), lymphocytes (N = 10188) 
and granulocytes + monocytes (N = 8411) follows exponential distribution with µ values 
as 47.42, 86.43 and 79.02 ms respectively as shown in Figure 3.6a. The µ value increases 
as the number of the cells decreases in the solution. As the experiment progresses in time, 
the µ value of exponential distribution for an increment of one minute would decrease. 
Figure 3.6b shows this decrease in the inter-cell time spacing for leukocytes, lymphocytes 
and granulocytes + monocytes. No cells appear for the initial 2 minutes after the blood 
infuses into the chip, and the lysing and quenching process initiates as represented by (A) 
in Figure 3.6b. Cells get diluted, resulting in higher inter-cell time spacing of almost 1 sec 
as the cells starts to appear at the counting region (B) comprising only lymphocytes. 
Granulocytes + monocytes appeared 30 sec late (C), as they get diffused less as compared 
to lymphocytes [40]. Granulocytes + monocytes stop appearing 3 minutes before the end 
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of the experiment (D) as compared to lymphocytes as a result of less diffusion into the 
buffer.      
	  
Figure 3.6: The time difference between the cell appearances follows an exponential 
distribution. (a) The inset shows that the spacing in between cells follows an exponential 
distribution. The inter-cell spacing of total leukocytes, lymphocytes and granulocytes + 
monocytes follows exponential distribution with µ as 47.42, 86.43 and 79.02 msec 
respectively. (b) The plot shows the µ value of exponential distribution for each minute 
for the entire experiment. (A) Blood infuses into the chip, and the lysing and quenching 
process initiates, no cells appear for initial 2 minutes, (B) cells gets diluted resulting in 
higher inter-cell time spacing of 1 sec, (C) granulocytes + monocytes diffused less as 
compared to lymphocytes and thus appear 30 sec late, (D) granulocytes + monocytes stop 
appearing 3 minutes before lymphocytes [40].     
3.6.  Doublet/Triplet Characterization  
It is characteristic of the Poisson process that the random events occurs in bursts or 
clumps, i.e. more than one event occurs in a specified interval. The probability of getting 
Poisson clumps can be obtained from Equation 3.3, where λ is the average number of 
events occurring in the specified time interval and k is the number of “event clumps” 
occurring in that time interval. Figure 3.7a shows the conceptual schematic for the 
occurrence of event clumps in specified time intervals, which follow a Poisson 
probability function. The entire experiment duration is divided into the time intervals of 
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120 seconds [40]. Figure 3.7b shows the Poisson distribution of cell counts for interval of 
120 sec during 5-7 min of experiment duration. The time interval for which average 
number of events is 1, i.e. λ = 1, is found by dividing the total time of 120 seconds by the 
total number of cells occurring in this duration. Using Equation 3.3, the probability of 0, 
2 (doublet) and 3 (triplet) cells appearing for the entire experiment duration of 15 minutes 
is shown in Figure 3.7c. The solid black lines represent the theoretical probability values 
of 36.79%, 18.39%, and 6.13% respectively [40].  
	  
Figure 3.7: (a) Occurrence of event clumps follows the Poisson probability function. (b) 
The Poisson distribution of cell counts for interval of 120 sec. (c) The probability of 0, 2 
and 3 cells appearing in intervals of 120 sec for the entire experiment duration of 15 
minutes. The solid black lines represent the theoretical probability values of 36.79, 18.39, 
and 6.13% respectively [40].  
3.7. Dilution Factor Estimation	  
High concentration of blood cells in the samples requires sample dilution for the accurate 
counting results. Assuming the initial concentration of the sample is C0 (cells/µL), with 
sample flowing at the flow rate of X (µL/min), the time interval ∆𝑡 (in seconds) for which 
λ is 1, is given as follows [40]:  
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∆𝑡 =    60𝐶!  𝑋                                                                                                                                                                                                                                                                         (3.6) 
Based on the Poisson theory of counting cells, the required dilution factor (DF) can be 
estimated by the following equation: 
𝐷𝐹 =    𝑇∆𝑡  𝜆!                                                                                                                                                                                                                                                                   (3.7) 
where 𝑇 = 𝑒𝑣𝑒𝑛𝑡  𝑡𝑖𝑚𝑒   ∗   𝑠𝑒𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛  𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡. Event time is the average time 
required for the event to occur, e.g. in our case a bipolar pulse width of 80 µs, 
representing a cell. The separation coefficient is defined as the time spacing (in multiples 
of time event) required in between two events. 𝜆! is the lambda value to get the required 
probability P which can be found using Equation 3.3. The dilution factor estimation 
problem can be formulated to find the dilution factor required using Equations 3.6 and 
3.7 so that no more than 2 cells occur in a time interval with a probability of, e.g., 0.5 
[40].  
3.8. Discussion 
The Poisson counting process characterization can be used for any other particle counting 
application. Here, we have shown that our cell counting process is a non-homogeneous 
Poisson process, as the λ value changes over time because of the cell diffusion in the 
buffer. However, other particle counting processes can be homogenous Poisson processes 
provided that there is no diffusion of the particles in the buffer that is pushing the sample 
in flow-based systems.  Thus, it is important to characterize the effectiveness of the “push 
buffer,” which can be done by measuring the skewness of the log-normal distribution of 
the cell/particle counts over experiment time. In samples with heterogeneous cell/particle 
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population w.r.t. size, the diffusion should be characterized for each individual type for 
accurate counting results. In high particle concentration samples, e.g. erythrocyte 
counting in diluted blood samples [45], a portion of the sample is usually selected for cell 
counting [40]. In such applications, characterizing the effectiveness of the buffer by 
measuring the diffusion of the cells in the buffer is extremely important while selecting 
the sample portion for accurate counting results.  
3.9. Conclusion 
Particle counting process characterization is important for accurate counting results. In 
this chapter, we characterized the electrical cell counting process in a microfluidic 
impedance cytometer and showed it to be a non-homogenous Poisson process. We 
demonstrated that lymphocytes diffused more in buffer as compared to granulocytes and 
monocytes. In samples with heterogeneous cell populations, individual cell diffusion 
characteristics should be considered, especially if a portion of the sample is being 
selected for accurate counting results. Our cell diffusion analysis can be used for 
characterizing buffer effectiveness to push the samples, which is critical in accurate cell 
counting. We also show that the time difference between the cell occurrences follows an 
exponential distribution [40].  The probability of occurrence of more than one cell in 
specified time intervals is also characterized. We used the Poisson statistics to estimate 
the sample dilution required for samples with high concentrations of cells as this limits 
the time, throughput, and the volume of the reagents used in the device.   
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CHAPTER 4 
CD4+/CD8+ T CELL COUNTING FOR 
HIV/AIDS DIAGNOSTICS  
4.1. Introduction  
Roughly 33 million people worldwide are infected with the human immunodeficiency 
virus (HIV); disease burden is highest in resource-limited settings. The CD4+ T cell 
count is a critical test in the management of HIV/AIDS, and is widely used to determine 
when to initiate antiretroviral therapy (ART) and to monitor the efficacy of treatment. Of 
the 33 million people living with HIV globally, 7.5 million are eligible for treatment but 
may not be aware of their CD4+ count [41]. The CD4+ count is usually expressed as the 
absolute number of CD4+ T lymphocytes per microliter of blood. In addition, the ratio of 
CD4+ cells to the total lymphocyte count (the CD4 percentage) and the ratio of CD4+ T 
cells to CD8+ T cells (CD4:CD8) is particularly useful in monitoring the course of 
infection and gives an overall assessment of the body’s immune strength. This ratio is 
also especially useful for HIV-infected infants, as there is a dramatic increase in CD8 T 
cells while the depletion of CD4 T cells owing to HIV infection is not apparent in their 
early life [41]. The contents of this chapter are taken from our work published as 
"Microfluidic CD4+ and CD8+ T lymphocyte counters for point-of-care HIV diagnostics 
using whole blood," Science Translational Medicine, vol. 5, issue 214, p. 214ra170, 
2013.  
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4.2. Experimental Protocol  
The process layout of the microfluidic biochip is shown in Figure 4.1a. Ten microliters of 
whole blood and lysing reagent at the ratio of 1:12 is infused to lyse all the erythrocytes 
effectively. “Lysing region” is composed of serpentine fluidic channels to provide chaotic 
advection to effectively mix whole blood with the lysing buffer [41]. Lysing of the 
erythrocytes changes the osmolarity of the solution: thus a quenching buffer is infused to 
maintain the osmolarity and stop the lysing process to preserve remaining leukocytes 
[41]. The leukocytes are electrically counted as they pass through a counting channel of 
15x15 µm2 cross-section. A bipolar voltage cell pulse is generated for each passage of a 
cell over the electrodes. The amplitude of the bipolar pulse is proportional to the cell size. 
This allowed the cell differentiation based on their size. CD4+ and CD8+ T cell antibody 
is immobilized in the capture chambers. The specific cells, i.e. CD4+ and CD8+ T cells, 
are captured in their respective capture chambers. The remaining cells will be counted 
again at the exit of the capture chamber. The difference between the cell counts gives the 
number of captured CD4+ or CD8+ T cells.  
4.3. CD4+/CD8+ T Lymphocyte Capture 
We next calculated the efficiency of capture of CD4+ (or CD8+ T) lymphocytes using a 
chamber coated with CD4 (or CD8) antibodies. Whole-blood samples (10 µl) from 
healthy volunteers were analyzed on-chip at varying capture chamber shear stresses to 
find the optimal shear stress that would provide the highest capture efficiency, resulting 
in the most accurate representative CD4+ or CD8+ T cell count. For a planar capture 
chamber, the maximum capture efficiency of 44.5% was obtained at 0.088 dyn/ cm2. At 
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this shear stress, the cells have ample interaction time with the immobilized antibodies on 
the chamber floor. By contrast, at 0.333 dyn/cm2, the capture efficiency decreased 
dramatically [19, 20]. 
 
Figure 4.1: (a) The flow layout of the biochip to enumerate CD4 T cell from whole blood. 
After the blood infusion & lysing/quenching module, the entrance counter counts all the 
leukocytes. CD4 T cells deplete in the capture chamber and the remaining cells are 
counted by the exit counter. The difference of cell counts in between two counters gives 
the number of captured CD4+ or CD8+ T cells18. (b) The picture of the actual biochip. 
The size of the biochip is 3cm x 4cm [46].  	  
4.3.1. Capture efficiency optimization 
Adding pillars in the capture chamber could result in higher capture efficiency. Four 
different designs with varying spacing of 8 µm, 11 µm, 14 µm, and 17 µm between posts 
were explored. We found that the 11µm post spacing provided small enough spacing to 
give the ~8 µm diameter lymphocytes contact with the antibody-coated pillar surfaces, 
but large enough to prevent larger leukocytes from clogging the pathways (Figure 4.2a). 
With a capture chamber footprint of 2.5 cm × 1.4 cm and 40-µm diameter posts with 11-
µm spacing, the total number of posts in the capture chamber was approximately 
134,000.  On-chip lysed and quenched blood samples were injected into the capture 
chamber at flow rates ranging from 15 to 30 µL/min to find the optimal shear stress for 
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maximum capture efficiency. This capture chamber design was simulated in COMSOL to 
get the corresponding shear stress values at the surface of the pillars for the different flow 
rates (Figure 4.2b). Two-dimensional simulation for a flow rate of 20 µL/min resulted in 
a maximum shear stress of 0.11 dyn/cm2 at the pillar walls (Figure 4.2b) with maximum 
capture efficiencies of 98.3% and 90.1% for CD4+ T cells and CD8+ T cells, respectively 
(Figure 4.2c).  
The capture of different cells in the capture chamber was investigated for both 
CD4 and CD8 T cell capture experiments (Figure 4.2d). Ten percent of lymphocytes 
other than CD4+ T cells and 52% of monocytes/granulocytes were captured in a CD4 
capture experiment. Twelve percent of lymphocytes other than CD8+ T cells and 48% of 
monocytes/granulocytes were captured in a CD8 capture experiment. In order to verify 
the capture of the CD4+ or CD8+ T cells, the cells in the capture chamber were labeled 
with CD4 and CD14 antibodies (CD14 can be used to differentiate monocytes) or CD8 
antibodies. The cells were further stained with DAPI for leukocyte determination and 
fixed with paraformaldehyde. Fluorescently labeled CD4+ and CD8+ T cells were then 
imaged in separate capture chambers to optically verify the cell capture (Figure 4.2e). 
Figure 4.2f shows the scatter plots of low-frequency impedance vs. opacity for a CD4+ T 
lymphocyte capture experiment. A gating technique—a region on a scatter plot to include 
all leukocytes, lymphocytes, and/or granulocytes/monocytes—similar to flow cytometry 
was used to determine the total lymphocyte counts for both entrance and exit counters 
(Figure 4.2f). The difference in counts obtained at the entrance and exit reflected the 
number of cells captured in the capture chamber.   
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Figure 4.2: Pillars in the capture chamber with result in high capture efficiency. (a) SEM 
image of the posts with height of 60 µm and diameter of posts is 40 µm. The spacing in 
between the posts is 11 µm. Scale bar, 40 µm. (b) The 2D shear stress simulation at 20 
µl/min in COMSOL. (c) Capture efficiency at different flow rates (shear stress) for CD4+ 
and CD8+ T cells. Data are means ± SD (n = 4).  (d) The capture efficiencies of different 
cell types. (1.) Lymphocytes other than CD4+ T cells captured by CD4 antibodies. (2.) 
Lymphocytes other than CD8+ T cells captured by CD8 antibodies. (3.) 
Monocytes/granulocytes captured by CD4 antibodies. (4.) Monocytes/granulocytes 
captured by CD4 antibodies. Data are means ± SD (n = 3).  (e) (left) False-colored 
fluorescent image of CD4+ T cells (green) captured in between posts in the capture 
chamber. (right) False-colored fluorescent image of CD8+ T cells (green) captured in 
between posts in the capture chamber. Scale bars, 40 µm. (f) CD4+/CD8+ T cell counting 
method. Opacity vs. low-frequency impedance scatter plots of a CD4+ T lymphocyte 
capture experiment.  Figure continues on next page.  
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The capture purity—or percentage make-up of different captured cell types—
when anti-CD4 or anti-CD8 antibody was adsorbed in the capture chamber is shown in 
Figure 4.3. It was found that that, among captured cells, 43% were CD4+ and 42% were 
CD8+ T cells in their respective capture experiments. 
4.3.2. Capture efficiency protocol 
Two populations were analyzed for the percent of CD4+/CD8+ T cells (out of total 
lymphocytes) from the same blood source: (A) 10-µl whole blood samples that went 
through on-chip lysis and quenching, but were collected in a tube immediately after the 
quenching process and (B) 10-µl whole blood samples that went through the differential 
Figure'4.2''con.nued'
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counting process with capture chambers coated with anti-CD4 antibody (also including) 
on-chip lysis and quenching. Both populations were collected in tubes already containing 
a 1% BSA in PBS (pH 7.4) solution and immediately centrifuged (200 × g, 5 min) and 
resuspended in 200 µl of the BSA solution. This dilution of chip-waste in the BSA 
solution was necessary, as it was found to increase leukocyte vitality. Omitting this 
dilution step resulted in total loss of all leukocytes [19, 20].  
 
 
Figure 4.3: Capture purity of cells captured with CD4 and CD8 antibodies. The 
percentage of cells captured from one blood sample was found by taking the difference in 
populations (from flow cytometry) of lymphocytes, granulocytes/monocytes, and CD4+ 
or CD8+ T cells, before and after capturing the cells in the capture chambers [19]. 
Both samples were labeled with a cocktail of Alexa Fluor 488-conjugated mouse 
antibody to human CD4 (MHCD0420, Invitrogen), phycoerythrin-Cy7 (PE-Cy7)–
conjugated mouse antibody to human CD45 (25-0459-42, eBioscience), and peridinin 
chlorophyll protein-cyanine 5.5 (PerCP-Cy5.5)–conjugated mouse antibody to human 
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CD3 (45-0037-42, eBioscience) using the manufacturer's suggested protocols to 
fluorescently isolate the CD4+ T lymphocytes (CD45+CD3+CD4+). The CD45 label was 
used to enhance the isolation of the lymphocytes from the other leukocytes, based on the 
lymphocytes' unique side scatter and CD45 receptor density characteristics [19, 20]. After 
labeling for 30 minutes, 1% BSA in PBS (pH 7.4) was added to each sample before 
washing (200 × g, 5 min) and resuspending the cells in the BSA solution before flow 
analysis using a Guava EasyCyte Plus flow cytometer (Guava Technologies, Inc.). 
4.3.3. Antibody adsorption in capture chamber 
Selective capture of CD4+ or CD8+ T lymphocytes from leukocytes was attained by 
coating the capture chamber region via simple adsorption with CD4 or CD8 antibody 
before electrical differential experiments. To obtain CD4 and CD8 counts from one 
patient, two chips were used simultaneously—one with a capture chamber modified with 
CD4 antibody, the other modified with CD8 antibody. Specifically, purified mouse 
antibody to human CD4 (clone 13B8.2; IM0398, Beckman Coulter, Inc.) or purified 
mouse antibody to human CD8 (clone 3B5; MHCD0800, Life Technologies) was diluted 
(8 µL Ab + 120 µL PBS in pH 7.4) and then injected into the capture chambers. The 
solution was then incubated for 30 minutes before a second infusion and subsequent 
incubation period of at least 30 minutes. The chips were either used immediately after the 
final incubation period, or stored in a 4°C refrigerator for experiments that would be 
performed on the same day as antibody coating. The antibody solution was washed out 
with pH 7.4 PBS immediately before counting experiments [19, 20]. 
 
65	  
	  
4.4. CD4+/CD8+ T Cell Count Comparison to Flow Cytometry 
Blood samples from 18 healthy volunteers and 32 HIV-infected patients undergoing 
antiretroviral therapy were analyzed for CD4+ and CD8+ T cell counts using our 
electrical differential counting technique with on-chip sample preparation [47, 48]. 
Electrical differential counting was compared to flow cytometry for CD4+ and CD8+ T 
cells and for the CD4:CD8 ratio from healthy volunteers (Figure 4.4) and HIV-infected 
subjects (Figure 4.5).  
Bland-Altman analyses showed good agreement between both counting methods 
over the entire CD4+/CD8+ T cell counting range for healthy samples. A positive bias of 
almost 24 cells/µL showed that, on average, the biochip gave slightly higher CD4 counts 
than the hospital’s flow cytometer (Figure 4.4a). CD8 counts resulted in a positive bias of 
9 cells/µL, showing even better accuracy (Figure 4.4b). A negligible bias of 0.012 existed 
for the CD4:CD8 ratio (Figure 4.4c). The microchip’s counting accuracy was quantified 
by finding the absolute average percent error (difference normalized by flow cytometry 
count) between the two methods.  The error was found to be 2.9% for CD4, 1.6% for 
CD8, and 1.9% for the CD4:CD8 ratio.  
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Figure 4.4: CD4+ and CD8+ T cell count comparison between chip and flow cytometer 
control using healthy blood samples. (a) CD4+ T cells comparison. (b) CD8+ T cells 
comparison. (c) CD4:CD8 ratio comparison. For scatterplots, the solid line is a linear fit 
to data with y-intercept set to 0. Hematocrit (%) is also plotted on second axis. Bland-
Altman plots are provided for each comparison; in these plots, the dashed lines represent 
the upper and lower levels of agreement (95% confidence), while the solid blue line 
shows a bias. Outliers were removed using a two-tailed T distribution. The p-value of 
<0.0001 rejects the null hypothesis.  
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Figure 4.5: Repeatability of CD4 and CD8 T cell counts. Experiments were performed on 
healthy samples only. Experiment 1 (CD4) and Experiment 1 (CD8) show the CD4+ and 
CD8+ capture experiments respectively (n=5) using the first blood sample. In experiment 
2, a second blood sample is used to perform 4 repeats of the CD4+ count experiment. In 
experiment 3, a third blood sample is used to perform 3 repeats of the CD8+ count 
experiment. Coefficient of variation (CV) is also calculated for all the cases.   	  
The repeatability of the CD4 and CD8 T cell count from the same blood was also 
performed on healthy blood samples (Figure 4.5). For the same blood sample, 5 repeats 
were performed for both CD4 and CD8 and the coefficient of variation (CV) values were 
found to be 4.7% and 4.5%, respectively. Variation analysis for a CD4 count of a second 
(n = 4) and a CD8 count for a third (n = 3) sample resulted in CV values of 2.1% and 
1.4%, respectively. 
Figure 4.6 shows CD4+ T cell count, CD8+ T cell count, and the CD4:CD8 ratio 
for HIV-infected blood samples. A positive bias of 12 cells/µL shows that, on average, 
the chip gave higher CD4+ T cell counts than the flow cytometer (Figure 4.6a). However, 
the CD8 counts resulted in a negative bias of 55 cells/µL (Figure 4.6b). The chip 
counting error was found to be 5.3% for CD4, 7.4% for CD8, and 11.9% for the 
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CD4:CD8 ratio. The high correlation (R2 ≥ 0.89; Figures 4.4 and 4.6) and high 
repeatability (CV ≤ 4.7%; Figure 4.5) of cell counts from our device compared with the 
‘gold standard’ of flow cytometry suggest that this electrical differential counting method 
with on-chip sample preparation could be a viable technology to provide portable and 
rapid CD4+ and CD8+ T cell counts for patients in resource-poor regions. 
4.5. Discussion   
The on-chip lysing and quenching techniques used in this study proved effective in not 
only rapidly removing erythrocytes and their debris, but also in preserving leukocytes for 
immune-capture in the capture chamber. An erythrocyte lysis time of only a few seconds 
ensured all cells were ruptured for all tested samples, regardless of erythrocyte 
concentration (3.3 to 6.0 million cells per microliter of blood). Accordingly, we found no 
correlation between the accuracy of the chip’s measurements and the hematocrit level for 
all CD4+ and CD8+ T cell counts for both healthy and HIV-infected samples. A slight 
increase in lysis time may be implemented to ensure accurate CD4 or CD8 counts for 
patients with elevated erythrocyte counts (>6 million cells per µl). Short-term exposure of 
leukocytes to saponin during lysis can damage the membranes of some leukocyte subsets 
[19]. However, it does not affect cell morphology or membrane antigen expression, 
which is crucial for our counting technique. The modified quenching solution quickly 
brought the leukocytes back to optimal pH and osmotic conditions to preserve them at 
least for the duration of the experiment. 
The dual frequency electrical interrogation method [41] was successful in 
discriminating lymphocytes from debris and monocytes/granulocytes, allowing for 
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accurate counts simply by obtaining the difference between lymphocyte counts before 
and after exposure to the capture chamber. The low-frequency signal differentiated 
between lymphocytes (~8 µm diameter) and the larger granulocytes and monocytes (> 10 
µm) because a cell’s size is directly proportional to its impedance at low frequencies [19, 
27]. The high-frequency signal was used to further differentiate among the leukocytes 
and between cells and debris by observing particle capacitance [21, 23]. For example, 
monocytes have extensive ruffling and pronounced folds in their membranes that result in 
an increase in membrane capacitance over similarly sized neutrophils with less prominent 
ruffles and folds. However, unlike what Holmes et al. demonstrated [11], we were not 
able to distinguish between monocytes and granulocytes (thus grouped them together). It 
is possible that our coplanar electrode configuration—which is easier to implement than 
the vertical configuration used by Holmes et al.—may prevent us from seeing this slight 
difference in capacitance [11, 24]. A future enhancement would be to improve the current 
sensing geometry for better leukocyte differentiation.   
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Figure 4.6: CD4+ and CD8+ T cell count from infected patient blood samples 
comparison between chip and flow cytometry control. (a) CD4+ T cells comparison. (b) 
CD8+ T cells comparison. (c) CD4:CD8 ratio comparison from 20 samples for which 
both CD4+ and CD8+ cells were counted. For scatterplots, the solid line is a linear fit to 
data with y-intercept set to 0. Hematocrit (%) is also plotted on second axis. Bland-
Altman plots are provided for each comparison; in these plots, the dashed lines represent 
the upper and lower levels of agreement (95% confidence), while the solid blue line 
shows a bias. Outliers were removed using a two-tailed T distribution. The p-value of 
<0.0001 rejects the null hypothesis. 
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The addition of 11 µm-spaced pillars in the capture chamber improved CD4+ and 
CD8+ T cell capture efficiency two-fold over the planar chamber configuration. The 
pillars not only increased antibody-antigen interactions via increased chamber surface 
area, but also ensured the wall shear stress was within the optimal regime for lymphocyte 
capture: ~0.1 to 0.3 dyn/cm2. The chip’s high capture efficiency and sensitive electrical 
Coulter counting approach resulted in excellent correlation and accuracy when compared 
to a clinical flow cytometer—but counting bias did exist. For healthy samples, the 
positive bias for CD4 and CD8 counts may be attributed to the nonspecific capture of 
other lymphocytes. Monocytes weakly express the CD4 antigen and may also be captured 
at the low shear stresses in these experiments, thus additionally contributing to the CD4 
count bias. The relatively large negative bias obtained for CD8 counts for infected blood 
samples may be attributed to a lower capture efficiency of the CD8+ T cells as compared 
to CD4+ T cells, with the mechanism possibly being reduced cell surface receptor 
expression for infected patients [21]. The moderately positive bias of CD4+ T cells for 
infected patients may be from the combination of unwanted monocyte capture (positive 
bias) and poorer capture efficiency from reduced CD4 receptor expression (negative 
bias). The positive bias from nonspecific cell capture may be reduced via additional 
surface chemistry to ensure surface regions not adsorbed with antibodies are passivated 
from nonspecific cellular interactions. Slightly decreasing wall shear stress may increase 
the capture efficiency of lymphocytes that may express fewer surface receptors in 
infected patients; however, balance is needed to ensure that the monocyte capture does 
not increase significantly for CD4+ T cell counts. 
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Many have attempted to develop a more portable, automated, and less expensive 
CD4+ T cell counter but few have shown clinical success. The Alere Pima CD4 bench-
top system has been shown to be the most successful automated next-generation CD4 
counter in resource-poor regions, employing optical fluorescence detection in single-use, 
disposable test cartridges that provide CD4+ T cell counts in approximately 20 minutes 
[21]. In contrast, the device described in this chapter uses only electrical methods to 
interrogate blood samples, thereby eliminating the need for expensive detection optics 
(i.e., light source, lenses, filters, CCD). The lack of optics and self-referencing impedance 
sensing method in the analysis unit would consume less battery power and make it less 
susceptible to environmental changes, such as temperature, humidity, and mechanical 
shock or vibration. With further integration, the microfluidic biochips described here 
would be packaged as a single-use, disposable module that is inserted into a hand-held 
analysis unit, accepts finger prick blood samples, and contains all reagents. Modifying 
the capture chamber to handle higher flow rates could provide over twice the testing 
throughput of the Pima CD4. In addition, our device was shown to be at least as accurate 
as the Pima CD4 system, with a CD4 counting bias of 12 cells/µL, compared to the Pima 
CD4’s bias of -121 cells/µL over similar CD4 T cell concentration ranges in HIV-
infected patient samples. For CD4 T cell counts less than 250 cells/µL, our device was 
comparable, with a bias of 9, compared to the Pima CD4’s bias of -10.8 [21]. The CV of 
the counter chip for CD4+ T cell counts from healthy samples was 2.1 to 4.7% (two 
samples, 4–5 replicates), which is less than the 10.7% CV for the Pima CD4 with patient 
samples (103 samples, duplicates).  Our chip has CV values that are considerably less 
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than the accepted standard of 15% for flow cytometry, which would also be a suitable 
standard for translation to point-of-care. 
In conclusion, the microfluidic device described in this study shows potential to 
accurately count CD4+ and CD8+ T cells from a drop of blood and allow HIV/AIDS 
diagnostics to penetrate resource-poor regions of the world. In addition to HIV/AIDS, our 
technology could also be used for individualized cell counting of other cell types in 
various settings, including at home, in doctors’ offices, and at the hospital bedside.  
4.6. Study Methods 
4.6.1. Study design 
To achieve a < 5% standard error of mean (SEM) for the microfluidic CD4:CD8 T cell 
counts  when compared to the flow cytometer’s counts, and assuming  standard deviation 
of 200 cells/µL for healthy donors (typical value of 1000 cells/µL), a minimum of 16 
samples would be needed. This is found by using the statistical relation that SEM = σ 
/√n, where σ is the standard deviation and n is the number of samples. After performing 
our experiments, we found the standard deviation amongst the healthy donor CD4+ T cell 
count is ~180 cells/µL, with a mean of 855 cells/µL (Fig. 4.4a).  
The biochip's CD4+:CD8+ T cell counts were compared to the ‘gold standard’ 
flow cytometry obtained from Carle Foundation Hospital, Urbana, IL. Eighteen healthy 
and 32 HIV-infected blood samples (10-µL volume) were evaluated using the electrical 
differential counting technique. The blood samples were used within 24 hours of 
acquisition. Infected samples were selected randomly from HIV-infected patients at the 
Champaign-Urbana Public Health District (CUPHD) as they came regularly for blood 
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cell counts.  The patients were asked to participate in the study by the CUPHD 
caseworkers. If they consented, then their blood samples were used in our devices for 
counting of the target cells. We collected individual samples from one to two HIV-
infected patients each day. The patients were not informed of the outcome of the 
diagnostic results from our device or from the flow cytometry controls, as per the UIUC 
Institutional Review Board (IRB) protocol. The samples were taken anonymously, such 
that the authors had no knowledge of the donor’s identity, age, gender, or ethnicity. 
Assessment of the outcomes was blind as the control counts from flow cytometry were 
obtained after the biochip experiments were completed.  
4.6.2. Blood sample acquisition  
The patient blood samples were obtained from Champaign-Urbana Public Health District 
according to the UIUC IRB protocol. Blood samples were obtained from volunteers using 
an informed consent process and monetary compensation approved by the UIUC IRB. 
Blood was collected via venipuncture in EDTA-coated BD Vacutainers (BD 
Biosciences), and kept on sample rotisserie at room temperature until experiments were 
performed. Healthy blood donors were recruited among UIUC students with reasonable 
monetary compensation via another approved UIUC IRB protocol [19, 20]. 
4.6.3. Chemicals and reagents 
Purified mouse antibody to human CD4 (clone 13B8.2; IM0398, Beckman Coulter, Inc.) 
and purified mouse antibody to human CD8 (clone 3B5; MHCD0800, Life Technologies) 
were used to capture CD4 and CD8 T cells from the blood. Alexa Fluor 488-conjugated 
mouse antibody to human CD4 (MHCD0420, Invitrogen), phycoerythrin-Cy7 (PE-Cy7)–
conjugated mouse antibody to human CD45 (25-0459-42, eBioscience) and peridinin 
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chlorophyll protein-cyanine 5.5 (PerCP-Cy5.5)–conjugated mouse antibody to human 
CD3 (45-0037-42, eBioscience) were used in the capture efficiency experiments [19, 20]. 
4.6.4. Statistical analysis 
Bland-Altman analysis was used to measure the agreement between the two cell-counting 
methods used here: chip and flow cytometry. The Bland-Altman plot was obtained by 
plotting the difference of the two method’s measurements (chip count-flow cytometry 
count) with the mean of the two method’s measurements (average of chip count and flow 
cytometry control count for every blood sample). It generated a bias value that indicated 
a systematic difference between the measurements and was calculated by taking the mean 
of the difference of the measurements. The limits of agreement were calculated by 1.96 × 
standard deviation of the difference. Two-tailed p-values were also calculated.  
Pearson coefficient represented the linear relationship between the two methods 
from chip counts and flow cytometry control counts. Its value range is [-1, 1], with 1 
representing the perfect correlation of the two methods. Coefficient of determination was 
also calculated to measure the correlation between both techniques. The significance 
level alpha = 0.05 was obtained. P<0.0001 rejected the null hypothesis that there exists 
no correlation between chip and control counts. Statistical analyses were performed by 
XLSTAT (data analysis software for Microsoft Excel). 
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CHAPTER 5 
COINCIDENCE DETECTION OF 
HETEROGENEOUS CELL POPULATIONS 
FROM WHOLE BLOOD 
 
5.1. Introduction 
Individual cell counting in microfluidic impedance cytometers requires a Coulter aperture 
with microfabricated electrodes bonded to it. Occurrence of the cell counts is a 
mathematical Poisson process and coincidence can be mathematically described by 
Poisson clumping and can never be truly eliminated irrespective of the sample dilution 
[40, 46]. Coincidence detection is essential for accurate counting results and becomes 
more significant especially for counting specific target cells, e.g. CD4+ or CD8+ T cell.  
In heterogeneous samples, e.g. in blood, cell differentiation in all coincidence 
occurrences is essential in addition to the coincidence detection for accurate cell 
enumeration. Coincidence detection also becomes significant for erythrocyte counting 
from diluted whole blood. We have characterized coincidence detection and cell 
differentiation using our cell counting biochip. We characterized the cell coincidence 
occurrences into three main types based on the range of time delay at which the 
coincidence occurs. Cell differentiation becomes critically important in coincidence 
detection in samples with heterogeneous populations for accurate counting results [46]. 
The contents of this chapter are taken from our work published as "Coincidence detection 
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of heterogeneous cell populations from whole blood with coplanar electrodes in a 
microfluidic impedance cytometer," Lab. Chip, vol. 14, pp. 4370-4381, 2014.  
5.2. Experimental Protocol  
Ten microliters of whole blood and lysing reagent at the ratio of 1:12 is infused in the 
biochip to lyse all the erythrocytes effectively. Lysing of the erythrocytes changes the 
osmolarity of the solution; thus, a quenching buffer is infused at the (iii) inlet port to 
maintain the osmolarity and stop the lysing process to preserve remaining leukocytes 
[41]. The leukocytes are electrically counted as they pass through a counting channel of 
15x15 µm2 cross-section. A typical bipolar voltage pulse for a lymphocyte and a 
granulocyte/monocyte is shown in Figure 5.1a and Figure 5.1b respectively. The 
amplitude of the lymphocyte cell pulse is smaller as compared to granulocyte/monocyte.  
The average diameter of the lymphocytes is almost 7.8 µm, thus generating smaller 
amplitude pulses as compared to 12 µm average cell diameter of granulocytes + 
monocytes. Figure 5.1c shows the voltage signal acquired for 0.4 seconds during an 
experiment. The maximum amplitude of all the cell pulses is recorded when it is 3 times 
the standard deviation of noise. The corresponding pulse peak amplitude histogram is 
shown in Figure 5.1d. The blue dotted rectangular region represents all the leukocytes 
including two sub-populations, i.e. lymphocytes and granulocytes + monocytes. The right 
one represents granulocyte/monocyte population with higher pulse amplitude because of 
their larger size. To the left of the leukocyte population is erythrocyte debris and the 
rectangular region is selected by considering the minima in between erythrocyte debris, 
and leukocyte population. Signal-to-noise ratio (SNR) is found by calculating the root-
mean-square (rms) value of the electrical cell pulses and the rms of the noise for 150 
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samples shown by red dotted rectangular regions in Figure 5.1(a, b). SNR value for each 
cell is computed for both lymphocytes and granulocytes/monocytes and is also shown in 
the histogram in Figure 5.1d.  
	  
Figure 5.1: (a) A typical bipolar voltage pulse for a lymphocyte. (b) A typical bipolar for 
a granulocyte/monocyte. (c) The bipolar pulses are produced for each cell passage with 
its amplitude proportional to the cell size. The data shows electrical cell pulses recorded 
for 0.4 seconds.  (f) The peak amplitude of all the pulses is recorded above 3 times the 
standard deviation of noise. The corresponding pulse peak amplitude histogram is shown. 
Signal-to-noise ratio (SNR) is also shown in the histogram for all the cells and is found 
by calculating the root-mean-square (rms) value of the respective voltage pulses and the 
rms of the noise for 150 samples as represented by red dotted rectangular regions in (a) 
and (b) [46]. 
5.3. Cell Pulse Modeling and Simulation  
A bipolar electrical voltage pulse generated for each passage of a cell over the electrodes 
is a result of a differential signal of two unipolar pulses. As a cell moves over the 
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electrodes, it generates a unipolar pulse from A-C and B-D as shown by blue lines in 
Figure 5.2a. We modelled the cell pulse by the following mathematical function [46]: 
𝐶𝑒𝑙𝑙  𝑝𝑢𝑙𝑠𝑒 =                𝐴! sin 𝑡 ,               0 ≥ 𝑡 ≤ !!!−𝐴! sin(𝑡 − !!! ),      !!! ≥ 𝑡 ≥ 𝑇           (5.1)	  
where ‘T’ is the time a cell takes to move from A to D, equivalent to bipolar pulse width. 
The cell pulse from A-C is modelled as 𝐴! sin 𝑡 and from B to D as −𝐴! sin(𝑡 −!!! ),       with 𝐴!,𝐴!being the respective signal amplitudes. The resulting differential signal, 
a bipolar pulse, is shown in red. Cell pulse is simulated using the modelling Equation 5.1 
and compared with the experimental electrical cell pulse in Figure 5.2b. The difference 
between the experimental vs. simulated cell pulse shows that the impedance starts to 
change earlier than the position A, and ends after position D [46]. This happens as the 
electric field lines extend beyond points A and D; however, the electric field strength is 
small, thus producing a small impedance change. We estimated this time difference to be 
T/20 as shown in Figure 5.2c. The cell pulse is simulated after incorporating T/20 time 
difference and compared with the experimental electrical cell pulse as shown in Figure 
5.2d. This gives a fair approximation of the simulated cell pulse with the experimental 
electrical cell pulse.    
5.4. Cell Coincidence Characterization 
Coincidence detection is essential for accurate cell counting. In case of different cell 
types, it is not only important to identify that a coincidence occurs but also to 
differentiate in between different cell types. We have characterized the coincidence into 
three types based on the time delay at which the second cell appears in the detection area 
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i.e. T/20 time before position A as shown in Figure 5.2c. Type 1 is defined for the range 
of  (0  𝑡𝑜   !!!"], type 2 for  (!!!"   𝑡𝑜   !"!!" ], and type 3 for  (!"!!"   𝑡𝑜  𝑇] respectively and is shown 
in Figure 5.3. The ranges for the above types are selected to categorize and facilitate the 
differentiation between the coincidence cells [46].   
	  
Figure 5.2: Modelling of the electrical cell pulse [46]. (a) As a cell moves over the 
electrodes, it generates a unipolar pulse from A to C and B to D as shown by blue curves. 
The electrical pulse from A to C is modelled as 𝐴! sin 𝑡 and from B to D as 𝐴! sin(𝑡 −𝜃)  with 𝐴!,𝐴!being the signal amplitude and  𝜃 =    2𝑇5 . The resulting differential signal, a 
bipolar pulse, is shown in red. ‘T’ is the time a cell takes to move from A to D, equivalent 
to pulse width. (b) Shows the experimental and simulated electrical pulse with a cell 
model as represented in (a). (c) The difference between the experimental and simulated 
cell pulse suggests that the impedance starts to change earlier than position A, and end 
after position D by time equal to T/20. (d) Shows the comparison of the simulated vs. 
experimental electrical cell pulse while considering the cell model as given in (c).   
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Figure 5.3: Coincidence types characterization. Three types of cell coincidences were 
defined based on the time delay of the second cell appearance. Type 1 is defined for the 
range of  (0  to   !"!"], type 2 for  (!"!"   to   !"#!" ], and type 3 for  (!"#!"   to  T] respectively. The 
range for the types is selected based on differentiating the coincidence cells [46].     	  
5.4.1. Type 1 cell coincidence  
Type 1 cell coincidence occurs when the second cell enters the detection area within the 
time delay range of   0  𝑡𝑜   !!!" , resulting in increased pulse amplitude and pulse width. 
The pulse width increases by the amount equal to the time delay at which the cell 
coincidence occurs. Increase in the amplitude of cell pulse can be seen by measuring the 
slope for the cell pulse. Figure 5.4a shows the simulated cell pulse and its corresponding 
change in slope [46]. During the range of type 1 coincidence, i.e. 0  𝑡𝑜   !!!" , the slope is 
decreasing. In case of a cell coincidence at a time delay of 3T/20, the resulting simulated 
cell pulse is shown in Figure 5.4b. As the second cell enters in the detection area there is 
a sharp increase in amplitude indicated by blue arrow at the point of coincidence [46]. 
This sharp increase in the cell pulse amplitude at the point of coincidence i.e. 3T/20, 
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resulting in the sudden increase in slope at the corresponding coincidence point. An 
example of type 1 coincidence is shown in Figure 5.4c where an experimental cell 
coincidence is shown as indicated by the increase in pulse amplitude and the pulse slope 
at the point of coincidence.  
Differentiating the individual cell types with their corresponding peak cell pulse 
amplitudes from the coincidence signal is essential for accurate cell counting [46].  Type 
1 coincidence results in increased amplitude of the coincident cell pulse. The peak 
amplitude of the coincident cell pulse is given by 
𝐴! + sin  (𝑡!)𝐴!                                                                                                                                                                                                                                                  (5.2) 
where  𝐴! and  𝐴! are the peak amplitudes of the first and coincident cell pulses 
receptively. 𝑡!  is the point of time delay at which coincidence occurs, which can be found 
by finding the point during 0  𝑡𝑜   !!!"  at which the decreasing slope of the corresponding 
cell pulse starts increasing. We have simulated the ratio of the slope difference (at the 
coincidence point) to the coincident pulse peak amplitude and plotted w.r.t. different 
values of the cell size ratios (A1/A2) for the whole range of type 1 coincidence 0  𝑡𝑜   !!!"  
as shown in Figure 5.4d. A1 is the pulse amplitude proportional to the size of the first cell 
and A2 is the pulse amplitude proportional to size of the second cell. After finding the 
ratio of the change in the slope at coincidence point to the peak amplitude of the 
coincidence pulse, Figure 5.4d can be used to find the value of A1/A2 by looking at the 
corresponding coincidence time plot [46]. The value of A1/A2 along with Equation 5.2 
can be used to differentiate the individual pulse amplitudes of coincidence cells from the 
resulting coincident cell pulse.  	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Figure 5.4: Type 1 cell coincidence characterization. (a) Shows the simulated cell pulse 
and its corresponding change in slope. (b) In case of a cell coincidence at 3T/20, the 
resulting simulated cell pulse is shown. As the second cell enters in the detection area 
there is a sharp increase in amplitude indicated by blue arrow at the point of coincidence. 
The sharp amplitude increase results in the sharp increase in slope at the corresponding 
point of coincidence. (c) Experimental cell coincidence is shown as indicated by the 
increase in pulse amplitude and the pulse slope at the point of coincidence. (d) The 
simulated ratio of the slope difference to the pulse peak amplitude is plotted w.r.t. 
different values of the cell size ratios (A1/A2) for a range of coincidence time delays for 
type 1 coincidence. A1 is the pulse amplitude proportional to the size of the first cell and 
A2 is the pulse amplitude proportional to size of the second cell [46].  
5.4.2. Type 2 cell coincidence  
Type 2 cell coincidence occurs when the second cell enters the detection area within the 
time delay range of  (!!!"   𝑡𝑜   !"!!" ]. The pulse width increases by an amount equal to the 
time delay at which the cell coincidence occurs. However, there is no increase in the 
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amplitude of first positive peak of the coincident pulse. The amplitude of the first positive 
peak represents the peak pulse amplitude of the first cell irrespective of the coincidence 
time delay because, at the time when the first positive peak appears, the second cell has 
not entered the detection area. The amplitude of the last negative peak represents the 
negative pulse amplitude of the second cell irrespective of the coincidence time delay 
because, by the time the last negative peak appears, the first cell has already left the 
detection area. The first positive peak and last negative peak differentiate both the cells. 
Figure 5.5a shows the simulated cell pulse when the second cell, twice the size of the first 
cell (A2 = 2A1), enters the detection region with time delay of 8T/20. The corresponding 
experimental electrical cell pulse as a result of type 2 coincidence is shown in Figure 
5.5b. The blue arrows at the first positive peak and last negative peak show the peak 
amplitudes to be considered for cell differentiation. When the second cell, equal in size to 
the first cell (A2 = A1), enters the detection region with time delay of 8T/20, the simulated 
cell pulse is shown in Figure 5.5c. The amplitude profile between the first positive peak 
and last negative peak depends on the coincidence time delay, and the individual pulse 
amplitudes of both cells. However, differentiating both cells only depends on the first 
positive and last negative peak and is independent of the amplitude profile in the middle. 
We have also shown in Figure 5.5d the simulated cell pulse when the second cell, equal 
in size to the first cell (A2 = A1), enters the detection region with time delay of 10T/20 
[46].     
85	  
	  
	  
	  
Figure 5.5: Type 2 cell coincidence occurs when a second cell enters the detection area 
with time delay in the range of (!!!"   𝑡𝑜   !"!!" ] [46]. (a) The simulated cell pulse when 
second cell, twice the size of first cell (A2 = 2A1), enters the detection region with time 
delay of 8T/20. (b) The experimental electrical cell pulse as a result of type 2 coincidence 
with blue arrows showing the peak amplitudes to be considered for cell differentiation. 
(c) The simulated cell pulse when second cell, equal in size to the first cell (A2 = A1), 
enters the detection region with time delay of 8T/20. (d) The simulated cell pulse when 
second cell, equal in size to the first cell (A2 = A1), enters the detection region with time 
delay of 10T/20.     
5.4.3. Type 3 cell coincidence  
Type 3 cell coincidence occurs when the second cell enters the detection area within the 
time delay range of  (!"!!"   𝑡𝑜  𝑇]. During this range of coincidence time delay, both the 
cells can be identified by the first and second positive peak amplitudes. In type 3 
coincidence the positive peak amplitude of the second pulse remains same irrespective of 
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the time delay at which coincidence occurs. We have simulated the cell pulses when the 
second cell, equal in size to the first cell (A2 = A1), enters the detection region with time 
delay of 14T/20 and 16T/20 as shown in Figure 5.6a.  As shown in Figure 5.6a, the first 
positive peak remains same irrespective of the coincidence time delay. The occurrence of 
the second positive peak associated with the second cell depends on the time delay at 
which the second cell enters the detection region; however, its amplitude is independent 
of the coincidence time delay.  The experimental electrical cell pulse when the second 
cell, slightly smaller than the first cell enters the detection region with time delay of 
18T/20 is shown in Figure 5.6b. 
	  
Figure 5.6: Type 3 cell coincidence Type 3 when a second cell enters the detection area 
with time delay in the range of (!"!!"   𝑡𝑜  𝑇]. (a) The simulated cell pulses when the second 
cell, equal in size to the first cell (A2 = A1) enters the detection region with time delay of 
14T/20 and 16T/20. In type 3 coincidence the positive peak amplitude of the second 
pulse remains the same irrespective of the time delay at which coincidence occurs. The 
positive peak amplitudes of both pulses are considered for cell differentiation. (b) The 
experimental electrical cell pulse when the second cell enters the detection region with 
time delay of 18T/20 [46].  
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5.4.4. Combined coincidence of multiple types  
Multiple coincidences occur when multiple cells enter at different time delays while 
generating a single electrical cell pulse. For example, we have simulated a multiple 
coincidence type case, when the second cell, half the size of the first cell, enters the 
detection area with time delay of 4T/20. The third cell (equal in size to the first cell) 
follows and enters the detection area with time delay of 8T/20 with respect to the first 
cell. The resulting simulated cell pulse, which is a combination of type 1 and type 2 
coincidences, is shown in Figure 5.7a. The corresponding experimental cell pulse is 
shown in Figure 5.7b. 
	  
Figure 5.7: Combination of difference coincidence types. (a) The simulated coincidence 
cell pulse, the second cell, half the size of the first cell enters detection area with time 
delay of 4T/20, the third cell (equal in size to the first cell) enters detection area with time 
delay of 8T/20 w.r.t. the first cell. (b) The experimental cell pulse with a combination of 
coincidence types 1 and 2 [46].  
5.5. Cell Counting Results with Coincidence Detection	  
Blood samples from healthy donors and HIV infected patients were collected for this 
study. CD4+ T and CD8+ T cell count is done with and without coincidence detection at 
both counters.  We compared CD4+ T cell count (n=10 healthy, n=10 HIV infected) from 
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our biochip and flow cytometer from Carle Foundation Hospital (Urbana, IL) with and 
without coincidence detection. Counting the cells with coincidence detection shows a 
high correlation with perfect slope (y = 1x, R2 = 0.99) as compared to cell counts without 
coincidence detection (y = 0.95x, R2 = 0.96). This improvement in counting results is 
reflected in the increase in the slope of the linear line comparing the biochip and the 
control counts from 0.95 (without coincidence) to 1.0 (with coincidence) as shown in 
Figure 5.8a, which ideally should be 1 for a perfect correlation. In order to see the 
difference more clearly, Bland-Altman analysis is also used to compare the biochip 
counts with flow cytometry control counts. A negative bias of 37 cells/µL shows that our 
biochip is counting, on average, 37 CD4+ T cells/µL less than the control counts without 
coincidence detection cell counting as shown in Figure 5.8b. CD4+ T cell counting with 
coincidence detection results in the bias value of about 4 cells/µL as shown in Figure 5.8c 
[46]. Figure 5.8d shows the comparison between CD8+ T cell count (n=10 healthy, n=10 
HIV infected) from our biochip and flow cytometer from Carle Foundation Hospital 
(Urbana, IL) with and without coincidence detection. Counting the CD8+ T cells with 
coincidence detection shows a high correlation with greater slope (y = 0.98x, R2 = 0.96) 
as compared to cell counts without coincidence detection (y = 0.93x, R2 = 0.96). A 
positive bias of 55 cells/µL shows that our biochip is counting, on average, 55 CD8+ T 
cells/µL more than the control counts without coincidence detection as shown in Figure 
5.8e. CD8+ T cell counting with coincidence detection results in the negative bias value 
of 19 cells/µL as shown in Figure 5.8f [46].  
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Figure 5.8: (a) CD4+ T cell comparison (n=20) with coincidence detection and without 
coincidence detection with flow cytometry control of Carle Hospital. (b) Bland-Altman 
plot to compare CD4 T cell count without coincidence detection. (c) Bland-Altman plot 
to compare CD4 T cell count with coincidence detection. (d) CD8+ T cell comparison 
(n=20) with coincidence detection and without coincidence detection with flow 
cytometry control of Carle Hospital. (e) Bland-Altman plot to compare CD8 T cell count 
without coincidence detection. (f) Bland-Altman plot to compare CD8 T cell count with 
coincidence detection [46].  
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The average % error in CD4+ T cell count is reduced from 8.2% (without 
coincidence) to 5.6% (with coincidence). Similarly, average % error in CD8+ T cell 
count is reduced from 7.9% (without coincidence) to 5.5% (with coincidence) as shown 
in Figure 5.9. This showed 46.6% improvement in accuracy of CD4+ T cell counts and 
43.5% in CD8+ T cell counts with coincidence detection as compared to without 
coincidence detection.   
 
Figure 5.9: The average % error in CD4+ T cell count is reduced from 8.2% (without 
coincidence) to 5.6% (with coincidence). The average % error in CD8+ T cell count is 
reduced from 7.9% (without coincidence) to 5.5% (with coincidence) [46].  
5.5.1. Discussion 
In our current study, we have used the three co-planar electrodes design which comprises 
the cell detection region of 75 µm. Reducing the length of the detection region will 
decrease the instances of the coincidences. The length of the detection region can be 
reduced by decreasing the width and spacing of the electrodes. This will result in reduced 
pulse width, and will require higher sampling rates to get optimum resolution (number of 
samples) in each cell pulse for accurate coincidence detection. It will further require 
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higher sampling rates, resulting in higher memory and processing speed requirements for 
accurate cell counting [46]. 
 Coincidence detection and cell differentiation requires extra data processing for 
type 1 as compared to type 2 or type 3. In real-time data processing, the cell pulse data 
needs to be stored and then processed to find the coincidence time delay from the slope of 
the cell pulse, and then further used to differentiate between individual cells. However, 
cell differentiation in type 3 coincidence does not require extra data processing as both 
cells can be identified from positive peak amplitudes automatically while regular cell 
counting.  
 Multiple coincidences can only occur for different types. More than 2 cells can 
never be present in any one coincidence region as the size of the coincidence region is 
almost 19, 26 and 30 µm for coincidence type 1, 2 and 3 respectively; however, the size 
of a typical leukocyte is about 8-12 µm, depending on the subtype of leukocyte. In other 
particle counting applications with size distribution much smaller than the coincidence 
region, the multiple coincidence of the same type can occur [46]. However, in the cell 
counting applications, like in CD4 and CD8 T cell count (for AIDS patients) from whole 
blood, the current co-planar electrode design is optimal to perform coincidence detection 
and individual cell differentiation for accurate cell counting.     
 Accurate counting of CD4+ or CD8+ T cell from our biochip also depends on 
other factors including the efficiency of erythrocyte lysing, preserving leukocytes, and 
capture efficiency of CD4+ and CD8+ T cells. However, cell counting with coincidence 
detection results in improved counting accuracy and a better correlation with control 
counts as shown in Figure 5.8 [46].   
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5.6. Conclusions 
Coincidence detection is essential for accurate counting results, especially for samples 
with small concentration of target cells.  In heterogeneous samples, e.g. in blood, cell 
differentiation in all the coincidence occurrences is essential in addition to the 
coincidence detection for accurate cell enumeration. In this chapter, we have 
characterized the coincidence detection with cell differentiation using our microfluidic 
impedance cytometer. We have determined an approximate mathematical model to 
simulate the electrical cell pulse and its coincidences. We show that coincidence 
detection can be characterized into three main types based on the range of time delay at 
which the cell coincidence occurs. We have characterized the cell differentiation in all the 
coincidence types. We also demonstrate the multiple coincidences of different types. We 
further used healthy and HIV infected patient blood samples to count the CD4+ and 
CD8+ T cells and have shown that the cell counting with coincidence detection gives 
more accurate results than cell counting without coincidence detection.  
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CHAPTER 6 
COMPLETE BLOOD CELL COUNT  
6.1. Introduction 
The complete blood count (CBC) is among the most ubiquitous diagnostic tests in 
primary care. CBC would be highly useful in acute radiation syndrome (ARS) where 
immediate CBC with differential is required for its rapid management of the disease. In 
chemotherapy and radiation therapy, the blood cell production needs to be monitored by a 
CBC. Inflammation, leukemia, tissue injury, bone marrow failure and immunodeficiency 
can be identified by the irregular WBC counts and their differentials. Similarly, bone 
marrow fibrosis, lymphoma, aplastic anemia and lupus erythematosus are associated with 
abnormal platelet count. Excessive bleeding, kidney bleeding, cancer and mechanical 
trauma can be identified by the RBC count. Thus, a microfluidic, disposable, economical 
CBC would help in monitoring all these diseases with more efficiency and care. Most of 
the commercially available machines are based on flow cytometry and Coulter detection 
principles [49].  
6.2. CBC Approach 
A schematic illustrating the overall approach for a chip capable of WBC counts (3 part 
differential), RBC counts, and platelet counts is shown in Figure 6.1. We will begin with 
drop of blood typically around 50 µL in volume (finger prick). From this, we will meter 
out 10 µL of blood to input to the chips. Since electrical differentiation of the cells is 
primarily based on size differences, platelets and RBCs can be differentiated electrically, 
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and the lymphocytes can be differentiated from other types of WBCs based on the 
observed pulse amplitude as discussed previously. 
Two separate chips will be used to obtain the 3-part WBC differential and the 
RBC/platelet counts. For WBC counts, the infused blood is exposed to lysing and 
quenching solutions as described previously to eliminate the RBCs from the solution. 
Platelets will still be present, but can be filtered out from the WBC counting results due 
to their size (1-2 µm for platelet size compared to >7 µm for WBCs). As shown in the top 
path in Figure 6.1, the solution now contains a mix of WBCs, including neutrophils 
(60%), lymphocytes (30%), monocytes (7.5%), eosinophils (3%), and basophils (<0.5%). 
Since fewer than 10 basophils are present per µL of blood, basophils will not be counted 
and can be ignored for the proof of concept experiments. This solution is flown through 
the entrance counter of the chip, resulting in a count that contains lymphocytes, 
neutrophils, monocytes, and eosinophils. At this point, a total lymphocyte count can be 
extracted since the lymphocytes can be separated based on their differing pulse 
amplitudes. The remaining cells are grouped into a population consisting of neutrophils, 
monocytes, and eosinophils. The solution will then be flowed into a capture chamber 
containing immobilized CD-14 antibodies to specifically capture monocytes, similar to 
the CD-4 and CD-8 capture chambers described previously. The resulting solution 
(containing lymphocytes, neutrophils, and eosinophils) is then flown through the exit 
counter.  This yields a second lymphocyte count, and a count of the neutrophils and 
eosinophils left in the solution. Since the eosinophil concentration is typically less than 
5% of that of the neutrophils, this count can be used as a rough neutrophil count. Finally, 
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the difference between the exit and entrance counts yields the monocyte count for the full 
3-part WBC differential count. 
For RBC and platelet counts (lower path in Figure 6.1), a dilution of the blood is 
necessary because the concentration of RBCs is extremely high (5 million per µL). The 
dilution factor will need to be optimized to maintain accurate counts without increasing 
the test time significantly. Initial experiments have diluted the blood by 100 times with 
PBS. After dilution, the RBCs and platelets can be counted using the same counting 
electrodes due to their difference in size. 
 
Figure 6.1: Schematic illustrating high level approach for 3 part differential WBC, RBC, 
and platelet count. 
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6.3. Theoretical Analysis for Differential Immuno-Capture Technique 
6.3.1. Accuracy for monocyte immuno-capture 
We have theoretically evaluated our differential counting technique for specific cell 
capture. The differential cell counter with specific cell capture is shown in Figure 6.2. Let 
the total granulocyte + monocyte population at the entrance counter be composed of C1 = 
M (monocyte) + G (granulocyte). Let M = aC1, where ‘a’ is percent monocyte 
comprising the entrance granulocyte + monocyte population. Similarly G = bC1, where 
‘b’ is the percent granulocytes comprising the entrance granulocyte + monocyte 
population.  
	  
Figure 6.2: The schematic of differential cell counting with the specific cell capture.  
Consider a case of the differential counting with specific monocyte capture. Let 
the specific monocyte capture efficiency be x% and the non-specific granulocyte capture 
be y%. The total captured cells in the capture chamber will be given as: 
𝐶𝑎𝑝𝑡𝑢𝑟𝑒𝑑  𝑐𝑒𝑙𝑙𝑠   𝐶𝐶 = 𝑥𝑀 + 𝑦𝐺 = 𝑎𝑥𝐶! + 𝑏𝑦𝐶! = 𝑎𝑥 + 𝑏𝑦 𝐶!                                                            (6.1) 
Percent error in the monocyte count can be calculated by the following equation: 
 𝐸𝑟𝑟𝑜𝑟   % =   𝑀 − 𝐶𝐶𝑀 =   𝑎 − (𝑎𝑥 + 𝑏𝑦)𝑎                                                                                                                                                       (6.2) 
 
We calculated the percent monocyte counting error with varying capture efficiency of 
monocytes and non-specific capture of granulocytes and shown in Figure 6.3. For 
Capture(Chamber(
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example, 90% monocytes capture efficiency and 10% non-specific granulocyte capture 
will give an 80% error in monocyte count.  
 
 
Figure 6.3: Percent monocyte counting error with varying capture efficiency of 
monocytes and non-specific capture of granulocytes. For 90% monocytes capture 
efficiency and 10% non-specific granulocyte capture, the % error in monocyte count is 
80%.  
6.3.2. Error estimation for any specific cell capture  
The generalized error equation and the limit of the differential cell counter are found by 
the following error analysis. Let ‘N’ be a distinct cell population obtained from the 
histogram of the entrance counter. Let 𝑁 = 𝐴 + 𝐵, where A and B are the two sub-
populations that comprise the total N cell population.  Let k be the percentage of N 
comprised of A cells such that  𝐴 = 𝑘𝑁.  Then B will be 𝐵 = 1− 𝑘 𝑁. We wish to 
capture cells of type A specifically, with capture efficiency of x% and non-specific B 
type cell. The total captured cells in the capture chamber will be given as: 
𝐶𝑎𝑝𝑡𝑢𝑟𝑒𝑑  𝑐𝑒𝑙𝑙𝑠   = 𝑥𝐴 + 𝑦𝐵 = 𝑘𝑥𝑁 + (1− 𝑘)𝑦𝑁 = (𝑘𝑥 − 𝑘𝑦 + 𝑦)𝑁                     (6.3) 
Percent error in the A cell count can be calculated by the following equation: 
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                             𝐸𝑟𝑟𝑜𝑟   % =   𝐴 − (𝑘𝑥 − 𝑘𝑦 + 𝑦)𝑁𝐴 =   𝑘 − 𝑘𝑥 + 𝑘𝑦 − 𝑦𝑘                                                                   (6.4) 
	  
We calculated the percent error in specific cell ‘A’ count with varying % levels of A cell 
population in the total cell population with 90% specific A cell capture and 10% non-
specific B cell capture as shown in Figure 6.4.  For less than 10% error in cell counts, the 
A cell concentration should be greater than 30% of the total N population. 
	  
Figure 6.4: Percent error in specific cell count with varying % levels of desired cell 
population in the total cell population with 90% specific cell capture and 10% non-
specific cell capture.  
6.4. Total WBC and 3-Part Differential Count 
6.4.1. Electrode design for accurate cell differentiation  
Electrode design is important to properly differentiate between different cell types, e.g. 
lymphocytes from granulocytes + monocytes. Figure 6.5 shows the schematic of the 
sensing region. Red circle represents a leukocyte in the middle of the two electrodes. The 
output voltage of the sensing region is measured as A-B. The peak of the voltage ‘A’ will 
% Monocytes comprising of total GM population 
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occur when the cell is exactly in the middle of the first two electrodes. Consider two 
cases. In first case, the spacing between the electrodes is greater than the cell diameter 
such that no portion of the cell is present over the second electrode, when the cell is in the 
middle of first two electrodes. The output voltage B will be zero in this case and the 
maximum pulse amplitude will be preserved. In the second case, the spacing between the 
electrodes is smaller than the cell diameter. When the cell is in the middle of first two 
electrodes, a portion of the cell will be over the second electrode, thus producing the 
output voltage B>0. The resulting differential signal A-B will lose the maximum 
amplitude of the pulse that corresponds to the cell size. Thus, for differentiating between 
different cell types, the electrode spacing should be greater than or equal to the maximum 
cell diameter that needs to be differentiated.   
	  
Figure 6.5: Schematic of the sensing region. Red circle represents a leukocyte in the 
middle of the two electrodes. The output voltage of the sensing region is measured as A-
B. The peak of the voltage ‘A’ will occur when the cell is exactly in the middle of the 
first two electrodes. The spacing between the electrodes should be enough that no portion 
of the cell is present over the second electrode such that B = 0.  This will preserve the 
peak of the voltage pulse corresponding to the size of the cell.   
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In order to effectively differentiate between lymphocytes from granulocytes and 
monocytes, the electrode spacing should be at least 15 µm, as the diameter of the 
granulocytes/ monocytes ranges from 12 to 15 µm. Figure 6.6(a) shows the cell voltage 
pulse amplitude histogram obtained with the sensing region consisting of the 5 µm 
spacing and width of the electrodes. Electrode spacing is less than the size of the cells, 
resulting in less accurate cell differentiation between lymphocytes and granulocytes + 
monocytes. Figure 6.6(b) shows the cell voltage pulse amplitude histogram obtained with 
the sensing region consisting of the 15 um spacing and width of the electrodes. Electrode 
spacing is greater than the size of the cells, resulting in more accurate cell differentiation. 
	  
Figure 6.6: Differentiation between lymphocytes with granulocytes and monocytes. (a) 
The cell voltage pulse amplitude histogram obtained with the sensing region consisting of 
the 5 µm spacing and width of the electrodes. Electrode spacing is less than the size of 
the cells, resulting in less accurate cell differentiation. (b) The cell voltage pulses 
amplitude histogram obtained with the sensing region consisting of the 15 µm spacing 
and width of the electrodes. Electrode spacing is greater than the size of the cells, 
resulting in more accurate cell differentiation.  
 
 
Lymphocytes+
Granulocytes+++
Monocytes+Lymphocytes+
Granulocytes+++
Monocytes+
a+ b+
101	  
	  
6.4.2. Off-chip lysing/ quenching with on-chip cell counting  
The blood is lysed off-chip with the lysing solution composed of saponin and formic acid 
with blood: lysing ratio of 1: 12. The lysing time is optimized for 6 s. The lysing process 
is halted as the quenching buffer composed of sodium carbonate and PBS is mixed with 
the solution. The blood-to-quenching ratio is adjusted to 1: 6.3. The prepared solution is 
passed through the microfabricated platinum electrodes of 15 µm width and 15 µm 
spacing. The input signal to the electrodes is 7 V and 303 kHz is multiplexed with 
1.7MHz. The data is acquired at the sampling frequency of 500 kHz. The histogram is 
plotted for the amplitude of the voltage pulses obtained and is shown in Figure 6.7.   
	  
Figure 6.7: The amplitude histogram as the leukocytes in the lysed blood pass through the 
counting channel. The lysing and quenching is done off-chip. The histogram shows the 
clear differentiation of the lymphocytes and granulocytes and monocytes.	  	  
Figure 6.8 shows the comparison of the absolute lymphocyte count from our 
biochip with the flow cytometry control (i.e. Sysmex cell counter) obtained from Carle 
Foundation Hospital, Urbana, IL. The figure shows the results of 9 samples. There is a 
Lymphocytes+
Granulocytes+++
Monocytes+
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good correlation between the two methods with R2 = 0.91 and with lymphocyte recovery 
of 83.8%. 
	  
Figure 6.8: Comparison of biochip total lymphocyte count with the flow cytometry 
control count (n=9). There is a good correlation in between the two methods with R2 = 
0.91 and with lymphocyte recovery of 83.8%.  
	  
Figure 6.9: Comparison of biochip total granulocyte + monocyte count with the flow 
cytometry control count (n=9). There is a good correlation between the two methods with 
R2 = 0.94 and with total granulocyte + monocyte recovery of 76.05%. 
Figure 6.9 shows the comparison of the total granulocyte + monocyte count from 
our biochip with the flow cytometry control (i.e. Sysmex cell counter) obtained from 
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Carle Foundation Hospital, Urbana, IL. There is a good correlation between the two 
methods with R2 = 0.94 and with granulocyte + monocyte recovery of 76.05%. 
The amplitude histogram of the voltage pulses obtained at high frequency of 1.7 
MHz for the granulocyte + monocyte population is shown in Figure 6.10. The 
distribution is fitted with the lognormal distribution function given by Equation 6.5. 
Considering that monocytes are slightly larger than neutrophils and the lysing/quenching 
reagents treat monocytes such that their membranes get less permeable than neutrophils, 
the normal distribution is skewed to lognormal distribution.  
𝑦 = 𝑓   𝑡   𝜇,𝜎) =    1𝑡𝜎 2𝜋 𝑒!(!"#!!)!!!!                                                                                                                                                                               (6.5)	  
 
	  
Figure 6.10: The amplitude histogram of the voltage pulses obtained at high frequency of 
1.7 MHz for the granulocyte + monocyte population. The distribution is fitted with the 
lognormal distribution.  
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The skewness of the fitted lognormal distribution to the high-frequency 
granulocyte + monocyte histogram is linearly correlated with the control monocyte + 
eosinophil concentration with an R2 = 0.86 as shown in Figure 6.11.    
	  
Figure 6.11: The skewness of the fitted lognormal distribution to the high-frequency 
granulocyte + monocyte histogram is linearly correlated with the control monocyte + 
eosinophil concentration with an R2 = 0.86.   
Equation 6.6 is used as a fudge factor to calculate the biochip monocyte + 
eosinophil concentration from the skewness of the fitted lognormal distribution of the 
high-frequency histogram of granulocyte + monocyte population. Figure 6.12 shows the 
comparison of the control monocyte + eosinophil count with the biochip’s calculated 
monocyte + eosinophil count using Equation 6.6 as a fudge factor. It gives a good 
correlation with an R2 = 0.845.  
(𝑀𝑜𝑛𝑜.+𝐸𝑜𝑠𝑖. ) 𝑐𝑜𝑢𝑛𝑡𝑢𝐿 =   1645.5 𝑠𝑘𝑒𝑤𝑛𝑒𝑠𝑠 −   1738.2                                                                                              (6.6) 
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Figure 6.12: Comparison of the control monocyte + eosinophil count with the biochip’s 
calculated monocyte + eosinophil count using Equation 6.6 as a fudge factor. It gives a 
good correlation with an R2 = 0.845.  
Biochip neutrophil count can be calculated by the following equation: 𝐵𝑖𝑜𝑐ℎ𝑖𝑝  𝑛𝑒𝑢𝑡𝑟𝑜𝑝ℎ𝑖𝑙  𝑐𝑜𝑢𝑛𝑡   = 𝑙𝑜𝑤  𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦   𝑔𝑟𝑎𝑛𝑢𝑙𝑜𝑐𝑦𝑡𝑒 +𝑚𝑜𝑛𝑜𝑐𝑦𝑡𝑒 𝑐𝑜𝑢𝑛𝑡 −0.76  ×(𝐵𝑖𝑜𝑐ℎ𝑖𝑝  𝑀𝑜𝑛𝑜.+𝐸𝑜𝑠𝑖𝑛. 𝑐𝑜𝑢𝑛𝑡),                                                                                   (6.7) 
where Biochip Mono.+Eosin. count were obtained from Equation 6.6, and 0.76 value 
represent the recovery of the total granulocyte + monocyte population of the low 
frequency. Figure 6.13 shows the comparison of the control neutrophil count with the 
calculated biochip neutrophil count. The biochip neutrophil count is calculated using 
Equation 6.7. There is a good correlation with R2 = 0.92 and neutrophil recovery of 
76.18%. 
The percentage of the total neutrophils of the granulocyte + monocyte should 
remain constant from control results from the flow cytometer to results calculated from 
biochip counts. Figure 6.14 shows the comparison of the neutrophil percentage of the 
granulocyte + monocyte concentration from the flow cytometry control with the 
calculated biochip neutrophil percentage. There is a good correlation with R2 = 0.836.   
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Figure 6.13: Comparison of the control neutrophil count with the calculated biochip 
neutrophil count. The biochip neutrophil count is calculated using the Equation 6.7. 
There is a good correlation with R2 = 0.92 and neutrophil recovery of 76.18%. 
	  
Figure 6.14: Comparison of the percent neutrophil of the granulocyte + monocyte 
concentration of the flow cytometry control with the calculated biochip percent 
neutrophil. There is a good correlation with R2 = 0.836.   
6.4.3. On-chip lysing/ quenching with on-chip cell counting  
The erythrocytes are lysed effectively by infusing the lysing buffer (0.12% (v/v) formic 
acid and 0.05% (w/v) saponin in DI) in the microfluidic biochip. After the erythrocyte 
lysis the cell debris tends to clump and make “debris ghosts” which result in clogging of 
electrical cell counting aperture of 15 µm x 15 µm. The debris clump also produces an 
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appreciable change in impedance and would result in background baseline voltage noise. 
In our previous study we found that greater quenching time of about 48 sec results in 
providing the shear stress long enough to disassociate the erythrocyte debris clumps. 
However, adding the 48 sec in the biochip would not only increase the size of the chip 
but also result in high fluidic resistance of the biochip. Saponin helps in dissociating the 
debris. As the next step, we have changed the ratios in between blood: lysing.  
The blood is lysed on-chip with blood: lysing ratio of 1.75 : 12. The lysing time is 
optimized for 9 s. The lysing process is halted as the quenching buffer composed of 
sodium carbonate and PBS is mixed with the solution. The blood to quenching ratio is 
adjusted to 1.75 : 10. The prepared solution is passed through the microfabricated 
platinum electrodes of 15 µm width and 15 µm spacing. The input signal to the electrodes 
is 7 V and 303 kHz is multiplexed with 1.7MHz. The data is acquired at the sampling 
frequency of 500 kHz.  
The total white blood cell count is obtained from the low-frequency histogram. 
Figure 6.15 shows the comparison of biochip total WBC counts with the flow cytometry 
control count using 10 blood samples collected from patients admitted to the ICU (shown 
in red) and 13 blood samples from non-ICU donors. There is a good correlation between 
the two methods with R2 = 0.95 and with total WBC recovery of 68.35%.  
Figure 6.16 shows the comparison of biochip total lymphocyte count with the 
flow cytometry control count using 10 blood samples collected from patients admitted to 
the ICU (shown in red) and 13 blood samples from non-ICU donors. It shows a good 
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correlation between the two methods with R2 = 0.96 and with total lymphocyte recovery 
of 71.83%. 
	  
Figure 6.15: Comparison of biochip total WBC counts with the flow cytometry control 
count using 10 blood samples collected from patients admitted to the ICU (shown in red) 
and 13 blood samples from non-ICU donors. The lysing and quenching is done on-chip. 
There is a good correlation between the two methods with R2 = 0.95 and with total WBC 
recovery of 68.35%.  
Figure 6.17 shows the comparison of biochip total granulocyte + monocyte count 
with the flow cytometry control count using 10 blood samples collected from patients 
admitted to the ICU (shown in red) and 13 blood samples from non-ICU donors. It shows 
a good correlation between the two methods with R2 = 0.96 and with total granulocyte + 
monocyte recovery of 68.02%.  
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Figure 6.16: Comparison of biochip total lymphocyte count with the flow cytometry 
control count using 10 blood samples collected from patients admitted to the ICU (shown 
in red) and 13 blood samples from non-ICU donors. The lysing and quenching is done 
on-chip. There is a good correlation between the two methods with R2 = 0.96 and with 
total lymphocyte recovery of 71.83%.  
	  
Figure 6.17: Comparison of biochip total granulocyte + monocyte count with the flow 
cytometry control count using 10 blood samples collected from patients admitted to the 
ICU (shown in red) and 13 blood samples from non-ICU donors. The lysing and 
quenching is done on-chip. There is a good correlation between the two methods with R2 
= 0.96 and with total granulocyte + monocyte recovery of 68.02%.  
y"="0.7183x"
R²"="0.96051"
0"
500"
1000"
1500"
2000"
2500"
3000"
0" 500" 1000" 1500" 2000" 2500" 3000" 3500" 4000"
Bi
oc
hi
p'
Ly
m
ph
oc
yt
e'
co
un
t'/
μL
'
Control'Lymphocyte'count'/μL'
y"="0.6802x"
R²"="0.95636"
0"
2000"
4000"
6000"
8000"
10000"
12000"
0" 3000" 6000" 9000" 12000" 15000"
Bi
oc
hi
p'
(G
ra
n.
+M
on
o)
'c
ou
nt
'/
μL
'
Control'(Neut.+Mono+Eison)'count'/μL'
110	  
	  
To differentiate in between neutrophils vs. monocytes + eosinophil, we fitted the 
lognormal distribution to the high frequency histogram of the granulocyte + monocyte 
population. Non-ICU samples were selected for this study. The skewness of the fitted 
lognormal distribution to the high frequency granulocyte + monocyte histogram is 
linearly correlated with the control monocyte + eosinophil concentration with an R2 = 
0.833 as shown in Figure 6.18.    
	  
Figure 6.18: The skewness of the fitted lognormal distribution to the high-frequency 
granulocyte + monocyte histogram is linearly correlated with the control monocyte + 
eosinophil concentration with an R2 = 0.833. Non-ICU samples were selected for this 
study.  
Equation 6.8 is used as a fudge factor to calculate the biochip monocyte + 
eosinophil concentration from the skewness of the fitted lognormal distribution of the 
high-frequency histogram of granulocyte + monocyte population. Figure 6.19 shows the 
comparison of the control monocyte + eosinophil count with the biochip’s calculated 
monocyte + eosinophil count using Equation 6.8 as a fudge factor. It gives a good 
correlation with an R2 = 0.80.  
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𝑀𝑜𝑛𝑜.+𝐸𝑜𝑠𝑖. 𝑐𝑜𝑢𝑛𝑡𝑢𝐿 =   124.8 𝑠𝑘𝑒𝑤𝑛𝑒𝑠𝑠 + 370.74                                                                                              (6.8) 
 
Figure 6.19: Comparison of the control monocyte + eosinophil count with the biochip’s 
calculated monocyte + eosinophil count using Equation 6.8 as a fudge factor. It gives a 
good correlation with an R2 = 0.80.  
Biochip neutrophil count can be calculated by the following equation: 𝐵𝑖𝑜𝑐ℎ𝑖𝑝  𝑛𝑒𝑢𝑡𝑟𝑜𝑝ℎ𝑖𝑙  𝑐𝑜𝑢𝑛𝑡   = 𝑙𝑜𝑤  𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦   𝑔𝑟𝑎𝑛𝑢𝑙𝑜𝑐𝑦𝑡𝑒 +𝑚𝑜𝑛𝑜𝑐𝑦𝑡𝑒 𝑐𝑜𝑢𝑛𝑡 −0.68  ×  (𝐵𝑖𝑜𝑐ℎ𝑖𝑝  𝑀𝑜𝑛𝑜.+𝐸𝑜𝑠𝑖𝑛. 𝑐𝑜𝑢𝑛𝑡),                                                                                  (6.9) 
where Biochip Mono.+Eosino. count were obtained from Equation 6.6 and 0.68 value 
represents the recovery of the total granulocyte + monocyte population of the low 
frequency. Figure 6.20 shows the comparison of the control neutrophil count with the 
calculated biochip neutrophil count. The biochip neutrophil count is calculated using the 
Equation 6.9. There is a good correlation with R2 = 0.82 and neutrophil recovery of 
63.38%. 
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Figure 6.20: Comparison of the control neutrophil count with the calculated biochip 
neutrophil count. The biochip neutrophil count is calculated using Equation 6.7. There is 
a good correlation with R2 = 0.82 and neutrophil recovery of 63.38%. 
 
Figure 6.21: Comparison of the percent neutrophil of the granulocyte + monocyte 
concentration of the flow cytometry control with the calculated biochip percent 
neutrophil. There is a good correlation with R2 = 0.806.   
The percentage of the total neutrophils of the granulocyte + monocyte should 
remain constant between control results from flow cytometer and results calculated from 
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biochip counts. Figure 6.21 shows the comparison of the neutrophil percent of the 
granulocyte + monocyte concentration from the flow cytometry control with the 
calculated biochip neutrophil percentage. There is a good correlation with R2 = 0.806.   
The blood samples collected from the ICU patients sometimes have abnormally 
high number immature granulocytes ranging from 10-2200 cells /µL as compared to 10-
20 cells/ µL in healthy samples.  The high number of immature granulocytes will result in 
changing the skewness level of the fitted lognormal distribution. Thus, the regular 
correlation of skewness with the control monocyte + eosinophil count does not hold. 	  
6.4.4. Precision studies of WBC and its differential counting  
Repeated experiments were performed from a single blood sample to measure the 
precision of our cell counting experiments. Figure 6.22 shows the precision study for the 
total WBC, lymphocyte and granulocyte + monocyte counting from biochip in 
comparison with counts from the flow cytometer.  The different colored bars represent 
the mean, and the error bars represent the standard deviation of the cell recoveries for 
sample A, B and C with 7, 8, and 9 repeated experiments respectively.   
Table 6.1 shows that white blood cell recovery of samples A, B and C is very 
consistent with small standard deviations. However, lymphocytes show a high percentage 
of recovery and more precise measurement as compared to granulocyte + monocyte 
counts.  
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Figure 6.22: Precision studies for WBC, lymphocyte and granulocyte + monocyte 
counting from biochip in comparison with counts from the flow cytometer.  The different 
colored bars represent the mean and the error bars represent the std. of the cell recoveries 
for sample A, B and C with 7, 8, and 9 repeated experiments respectively.  	   
Table 6.1: Precision studies for WBC, lymphocyte and granulocyte + monocyte counting 
from biochip in comparison with counts from the flow cytometer. The table gives the 
mean and std. of the cells recoveries for sample A, B and C with 7, 8, and 9 repeated 
experiments respectively.   
 
Sample	  A	  
Mean	  
Recovery	  
(%) 
Sample	  B	  
Mean	  
Recovery	  
(%) 
Sample	  C	  	  
Mean	  
Recovery	  
(%) 
Sample	  A	  
std.	  
Recovery 
Sample	  B	  
std.	  
Recovery 
Sample	  C	  
std.	  
Recovery 
WBC	   64.6 64.5 65.2 6 6 3.9 
Lymphocyte 60.3 74.1 71.3 8.1 6.2 5.3 
Granulocyte	  
+	  Monocyte 67.1 57.1 63.8 10.5 8.2 5.4 
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6.5. Electrical Counting of Erythrocytes and Platelets 
6.5.1. Optimization of electronic settings and digital signal filtering  
Platelets, being the smallest (~ 1-2 µm diameter) of all the blood cell types, don not result 
in significant impedance change. We varied different voltage and gain settings to acquire 
the platelets signal. Figure 6.23 shows the amplitude histogram of the voltage pulses 
obtained as the cells in the diluted blood are passed through the counting region. Figure 
6.23(a) shows the histogram with voltage setting of the input voltage as 5 V with a 
differential amplifier gain of 10. The red arrow shows the zoomed-in version of the black 
dotted rectangle, which shows a smooth decrease of red blood cell distribution.  Figure 
6.23(b) shows the histogram obtained with the input voltage of 10 V and a differential 
amplifier gain of 10. The zoomed-in version shows an appearance of platelet distribution 
to the left of the red blood cell distribution.   
A typical voltage pulse corresponding to the red blood cell is shown in Figure 
6.24(a) with SNR of 21.7dB. A typical voltage pulse corresponding to the platelet with 
SNR of 11.4dB is shown in Figure 6.24(b). In order to obtain the maximum SNR for the 
pulses, the input voltage to the electrodes is varied from 1 to 10 V. Figure 6.25 shows the 
corresponding increase in the mean SNR of the red blood cells pulses with the increase in 
the input voltage. It shows a linear increase with an R2 value of 0.859.  
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Figure 6.23: The amplitude histogram of the voltage pulses obtained as the cells in the 
diluted blood pass through the counting region. (a) The input voltage is 5 V with a 
differential amplifier gain of 10. The red arrow shows the zoomed-in version of the black 
dotted rectangle, which shows a smooth decrease of red blood cell distribution.  (b) The 
input voltage is 10 V with a differential amplifier gain of 10. The zoomed-in version 
shows an appearance of platelet distribution to the left of the red blood cell distribution.   
	  
Figure 6.24: (a) A typical voltage pulse corresponding to the red blood cell, with SNR of 
21.7dB.  (b) A typical voltage pulse corresponding to the platelet, with SNR of 11.4dB.  
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Figure 6.25: The SNR for the pulses corresponding red blood cells increases with the 
increase of the input voltage to the electrodes with R2 = 0.859.  
The frequency spectrum of the cell counting experiment data will allow us to see 
the noise components in the frequency domain. Figure 6.26 shows the frequency 
spectrum of the entire cell counting data without performing any digital filtering. There is 
low-frequency noise in the data because of the baseline drifts, electronic noise, and power 
line interference (60 Hz). Most of the cells pulses spectrum lies in the range of 5 kHz to 
90 kHz as shown in Figure 6.26(a). There is an input frequency noise of 303 kHz and 
another high-frequency noise at 314.8 kHz as shown in Figure 6.26(b). These can be 
removed by using a low-pass filter with cut-off-frequency less than 303 kHz.  
The low-frequency noise in the data is removed by applying a high-pass filter of 
20 Hz.  To remove the power line frequency, a band stop filter is used with cut-off-
frequencies of (58, 62) Hz. The second harmonic of the power line frequency is also 
removed using a band stop filter with cut-off-frequencies of (118, 122) Hz. The baseline 
drift is also corrected. The frequency spectrum of the cell counting experiment data after 
signal filtering is shown in Figure 6.27.  
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Figure 6.26: Frequency spectrum of the cell counting experiment data before any signal 
filtering. (a) There is low-frequency noise in the data because of the baseline drifts, 
electronic noise, and power line interference (60 Hz). Most of the cell pulses spectrum 
lies in the range of 5 kHz to 90 kHz. (b) There is an input frequency noise of 303 kHz 
and another high-frequency noise at 314.8 kHz. These can be removed by using a low-
pass filter with cut-off-frequency less than 303 kHz.  
	  
Figure 6.27: Frequency spectrum of the cell counting experiment data after signal 
filtering. The low-frequency noise in the data is removed by applying a high-pass filter of 
20 Hz.  To remove the power line frequency, a band-stop filter is used with cut-off-
frequencies of (58, 62) Hz. The second harmonic of the power line frequency is also 
removed using a band-stop filter with cut-off-frequencies of (118, 122) Hz. The baseline 
drift is also corrected.  
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6.5.2. Chip noise characterization for platelet counting   
The blood is diluted off-chip with PBS with a ratio of 1: 300. The diluted blood is passed 
through the counting electrodes at 40 µL/min and the data is sampled at 1Ms/sec.  The 
amplitude histogram of the voltage pulses obtained is shown in Figure 6.28. The SNR for 
the red blood cell pulses was 39.73 dB and for platelets 12.94db. Figure 6.28(a) shows 
the histogram with the distinct RBC and platelet distributions. Figure 6.28(b) shows 
zoomed-in version of (a) from 0 to 1 V.    
	  
Figure 6.28: The amplitude histogram of the voltage pulses obtained as the cells in the 
diluted blood (Blood: PBS = 1: 300) is passed through the counting channel. The SNR 
for the red blood cell pulses was 39.73 dB and for platelets 12.94dB. (a) The histogram 
shows the distinct RBC and platelet distributions. (b) Zoomed-in version of (a) in 
between 0 to 1 Volts.    
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Figure 6.29: Characteristics of a chip for red blood cell and platelet counting. The voltage 
pulses obtained as the blood cells pass through the counting channel. The standard 
deviation of the noise in this case is less than 0.03 V. The baseline shift got removed after 
the filtering and baseline correction algorithm.  
	  
Figure 6.30: Characteristics of a chip for only red blood cell counting. The voltage pulses 
obtained as the blood cells pass through the counting channel. The standard deviation of 
the noise in this case is greater than 0.05 V (red dotted rectangle). After the filtering and 
baseline drift correction the baseline still shows a lot of abrupt changes in the amplitude 
(shown by red arrows).  
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Platelets, being the smallest, produce the least change in the impedance as they 
pass through the counting electrodes. In experiments for which we were able to see the 
platelet distribution; the standard deviation of the noise is less than 0.03 V. The baseline 
drift in the signal also got completely removed after the filtering and baseline correction 
algorithm as shown in Figure 6.29. However, for the experiments for which we were not 
able to see the platelet distribution, the standard deviation of the noise in the biochip is 
greater than 0.05 V. Also the baseline drift is huge compared to the good chips as shown 
in Figure 6.30. 
6.5.3. RBC and platelet counting with off-chip dilution 
 
The erythrocyte (red blood cell) concentration in the blood sample is significant 
and thus requires dilution for accurate cell counting. The RBCs can be differentiated from 
platelets and white blood cells from the electrical voltage pulse’s amplitude histogram as 
the RBC is bigger than a platelet but smaller than white a blood cell. The blood samples 
were diluted off-chip with different blood : PBS dilution ratios. We flow the diluted 
blood sample through our impedance cell counter and count all the pulses; the sample 
contains RBC, platelets and all WBC. The leukocytes comprise about 0.5% and platelets 
about 3-5% of the erythrocytes, and after dilution the leukocyte concentration in the 
sample becomes very low, around 50 cells/µL, resulting a negligible effect on the 
counting results. Figure 6.31 compares the control red blood cell counts with the counts 
obtained from the biochip using 22 blood samples. Blood is diluted with PBS at different 
dilutions (PBS : blood) and flown through the biochip. It shows a good correlation 
between the two methods with R2 = 0.96 and the cell recovery of 96.35%.  
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Figure 6.31: Comparison of the control red blood cell counts with the counts obtained 
from the biochip using 22 blood samples. Blood is diluted with PBS at different dilutions 
(PBS : blood) and flown through the biochip. It shows a good correlation between the 
two methods with R2 = 0.96 and the cell recovery of 96.35%.  
Figure 6.32 compares the control platelet counts with the counts obtained from 
the biochip using 13 blood samples. Blood is diluted with PBS at different dilutions (PBS 
: blood) and flown through the biochip. It shows a good correlation in between the two 
methods with R2 = 0.86 and the cell recovery of only 51%.  The decrease in the cell 
recovery can be associated with the high noise in the biochip, resulting in loss of platelet 
pulses in the noise. Platelets, being the smallest (~ 1-2 µm diameter), result in no 
significant impedance change 
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Figure 6.32: Comparison of the control platelet counts with the counts obtained from the 
biochip using 13 blood samples. Blood is diluted with PBS at different dilutions (PBS : 
blood) and flown through the biochip. It shows a good correlation between the two 
methods with R2 = 0.86 and cell recovery of 51%.  The decrease in the cell recovery can 
be associated with the high noise in the biochip resulting in loss of platelet pulses in the 
noise.  
6.5.4. Precision studies of RBC and platelet counting  
 
Repeated experiments were performed from a single blood sample to measure the 
precision of our red blood cell counting experiments.  Blood is diluted with PBS with a 
ratio of 1: 200 and flown at 40 µL/min through the electrical counter.  Figure 6.33 shows 
the precision results. ‘1’ shows the healthy donor sample with a CV = 2.6% for 5 
repeated experiments, ‘2’ shows a cancer donor sample with a CV = 5.5% for 5 repeated 
experiments, ‘3’ shows the cancer donor sample with a CV = 5.8% for 4 repeated 
experiments. 
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Figure 6.33: Precision studies of the red blood cell counting. 1 shows the healthy donor 
sample with a CV = 2.6% for 5 repeated experiments. 2 shows a cancer donor sample 
with a CV = 5.5% for 5 repeated experiments. 3 shows the cancer donor sample with a 
CV = 5.8% for 4 repeated experiments.  
Repeated experiments were performed from a single blood sample to measure the 
precision of our platelet counting experiments.  Blood is diluted with PBS with a ratio of 
1: 200 and flown at 40 µL/min through the electrical counter.  Figure 6.34 shows the 
precision results. ‘1’ shows the healthy donor sample with a CV = 10.2% for 5 repeated 
experiments, ‘2’ shows a cancer donor sample with a CV = 8.1% for 5 repeated 
experiments, ‘3’ shows the cancer donor sample with a CV = 9.3% for 4 repeated 
experiments. 
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Figure 6.34: Precision studies of the platelet counting. 1 shows the healthy donor sample 
with a CV = 10.2% for 5 repeated experiments. 2 shows a cancer donor sample with a 
CV = 8.1% for 5 repeated experiments. 3 shows the cancer donor sample with a CV = 
9.3% for 4 repeated experiments.  
6.5.5. RBC and platelet counting with on-chip dilution 
 
The on-chip dilution is performed on the biochip; the schematic is shown in Figure 6.35. 
The PBS and the blood are infused in the chips at the indicated inlet ports. The PBS is 
mixed with blood at the ratio of 40: 0.5 in the serpentine channels.  The electrical counter 
counted the cells in the diluted blood as they pass through the electrodes.  
The two-cell coincidence probability increases linearly with the volume of the 
sensing region (width and spacing of electrodes), as shown in Figure 6.36.  
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Figure 6.35: Schematic of the red blood cell and platelet counting biochip. PBS is mixed 
with blood at the ratio of 40 : 0.5 in the serpentine channels.  The electrical counter 
counted the cells in the diluted blood as they passed through the electrodes.  
 
Figure 6.36:  The two-cell coincidence probability increases linearly with the volume of 
the sensing region (width and spacing of electrodes).  
The Blood is diluted on-chip with PBS with flow rate ratio (Blood : PBS = 0.5 : 
40 µL/min). The resulting diluted blood is flown through the electrical counter. Figure 
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6.37 compares the control red blood cell counts with the counts obtained from the biochip 
using 21 blood samples. It shows a good correlation between the two methods with R2 = 
0.82 and the cell recovery of 80.62%. The decrease in the cell recovery can be associated 
with the high number of coincidences at the low dilution factor.  
 
Figure 6.37: Comparison of the control red blood cell counts with the counts obtained 
from the biochip using 21 blood samples. Blood is diluted on-chip with PBS with flow 
rate ratio (Blood : PBS = 0.5 : 40 µL/min) and flown through the biochip. It shows a 
good correlation in between the two methods with R2 = 0.82 and the cell recovery of 
80.62%.  The decrease in the cell recovery can be associated with the high number of 
coincidences at the low dilution factor.  
Figure 6.38 compares the control platelet counts with the counts obtained from 
the biochip using 13 blood samples. Blood is diluted on-chip with PBS with flow rate 
ratio (Blood : PBS = 0.5 : 40 µL/min) and flown through the biochip. It shows a good 
correlation between the two methods with R2 = 0.90 and the cell recovery of 67.85%.  
The decrease in the cell recovery can be associated with the high number of coincidences 
at the low dilution factor and loss of the platelets pulses in the noise. 
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Figure 6.38: Comparison of the control platelet counts with the counts obtained from the 
biochip using 13 blood samples. Blood is diluted on-chip with PBS with flow rate ratio 
(Blood : PBS = 0.5 : 40 µL/min) and flown through the biochip. It shows a good 
correlation in between the two methods with R2 = 0.90 and the cell recovery of 67.85%.  
The decrease in the cell recovery can be associated with the high number of coincidences 
at the low dilution factor and loss of the platelets pulses in the noise. 
6.5.6. Reducing chip noise to improve platelet counting   
	  
The signal averaging technique can be used to improve the signal-to-noise ratio. This 
technique only works if the noise is Gaussian white noise and not pink or brown noise, 
which have spectral characteristics of 1/f and 1/f2 respectively. We have shown the 
decrease in the standard deviation of chip noise with signal averaging. PBS is flown 
through the electrical counter at 40 µL/min and the chip noise is recorded. The measured 
standard deviation of the chip noise was 0.0873 V. Figure 6.39 shows the decrease in the 
standard deviation of the chip noise with signal averaging. Increased number of samples 
for averaging will result in decreased standard deviation for the chip noise. After 
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averaging with 2 samples, the standard deviation is reduced to about 0.06 V, which 
further decreased to 0.04 V after signal averaging with 3 samples.  
	  
Figure 6.39: The decrease in the standard deviation of the chip noise with signal 
averaging. Increased number of samples for averaging will result in decreased standard 
deviation for the chip noise. 
After performing the high-pass filtering at 20Hz and power-line filtering at 60 and 
120 Hz, the frequency spectrum of the RBC, platelet counting experimental data with the 
sampling rate of 1 MHz and input signal frequency of 303kHz are obtained and shown in 
Figure 6.40. The red arrow shows voltage pulse frequency spectrum. The green arrow 
show a peak at 303kHz, which can be further removed to decrease the chip’s noise. A 
low pass filter of 200kHz can be used to remove this noise. The standard deviation of the 
chip noise without using this filter was 0.0564 V, which decreased to 0.0305 V after low-
pass filtering was performed on the data with cut-off frequency of 200 kHz.  	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Figure 6.40: Frequency spectra of the RBC, platelet counting experimental data with the 
sampling rate of 1 MHz and input signal frequency of 303kHz. The red arrow shows 
voltage pulse frequency spectrum. The green arrow show a peak at 303kHz, which can be 
further removed to decrease the chip’s noise.   
6.5.7. Power analysis  
 
Power analysis is used to determine the sample size required to get the desired statistical 
values. In order to get the correlation coefficient, we set  ρ at 0.9 with an alpha level (two 
tailed) of 0.01 and power at 0.9. For ρ = 0.9, Zα = 2.58.  However, Zb = 1.28 for the 
desired 0.9 power level.  The following equation is used to calculate the require sample 
size, which gives N =13.   
𝑁 =    𝑍! +   𝑍! !14 𝑙𝑜𝑔! 1+ 𝜌1− 𝜌 ! + 3                                                                                                                                                                                                          (6.8)   
6.6. Impact on Primary Health Care 
CBC device exhibits the potential to improve patient care in a complete spectrum of 
settings. One of the compelling possibilities is in resource-limited settings where 
Pulses&Spectra&& Input&&frequency&&
noise&&
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laboratory tests are often inaccessible due to cost, poor laboratory facilities, and the 
difficulty of follow-up upon receiving results that take days to process. Ease-of-use and 
the ability to interface with mobile communication devices such as smartphones and 
tablets with wireless internet connectivity enable a point-of-care device by which rapid 
results can be transmitted to a provider anywhere in the world, eliminating the need for a 
highly trained professional at the site of care and thus reducing the cost.  
The wireless delivery of results to healthcare providers also enables use of the 
device in the home setting, particularly for patients with chronic conditions or those 
undergoing continued therapy that requires the monitoring of any one or multiple 
components of a CBC and white blood cell differential. Rapid results in a portable device 
carried on an ambulance will shape interventions in pre-hospital care and provide 
receiving emergency departments with CBC results upon arrival. When transport time is 
significant such as in rural settings, the CBC can provide an assessment of patient 
stability and can provide information to advise emergency medical technicians on further 
care. 
In the emergency department, a rapid CBC device promises faster results than the 
current capabilities of clinical laboratories and will decrease laboratory workload. It not 
only may speed up life-saving care in emergent cases, but also may improve emergency 
room throughput and ultimately decrease waiting time in busy hospitals. Upon a patient’s 
admission to full hospital care, this device can be used at the bedside to monitor the 
patient regularly in the hospital room, especially a patient in intensive care unit. Finally, 
this device can be used in the physician's office during regular visits for basic screenings 
or follow-up examinations that require blood counts to be performed. 
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CHAPTER 7 
SEPSIS DIAGNOSIS BASED ON CD64 
EXPRESSION QUANTIFICATION  
 
7.1. Introduction 
More than 5 million patients are admitted annually to intensive care units (ICUs) in the 
United States [50]. Of these, severe sepsis strikes more than 1 million people, or roughly 
20 percent of all ICU patients [51]. An estimated 28 to 50 percent of these people die 
(280,000-500,000), a number which is greater than the number of American deaths from 
prostate cancer, breast cancer, and AIDS combined [52]. A dominant factor underlying 
these surprisingly grim numbers is that septic patients have largely been treated as a 
single group despite the overwhelming evidence to the heterogeneity of the disease [53]. 
Several innovative treatment strategies are now available that can dramatically increase 
chances of survival if applied early enough in the appropriate situations, including 
antimicrobial therapies, immuno-stimulatory therapies, and immunosuppression therapies 
[54]. The normal course of sepsis includes an early inflammation of immune response 
followed by compensatory body mechanisms to prevent overwhelming inflammation, 
causing an immunosuppression response. These strategies thus need to be applied at 
exactly the right time for exactly the right patients. Every hour that appropriate 
antimicrobial medication is delayed can decrease 72-hour survival rates by roughly 7.7% 
per hour, underscoring the need for early diagnosis techniques [55]. 
133	  
	  
There is a critical need for a diagnostic method that could be used to predict the 
onset of infection, to define the optimal targeted and individualized therapy, and to 
provide feedback for maximized drug efficacy [54]. Ideally, such a strategy would 
diagnose the stage of patient sepsis with high accuracy, sensitivity, specificity, and 
frequency. A feedback mechanism by which the test could be performed every 30 
minutes to an hour would be ideal. To increase accuracy, sensitivity, and specificity, 
utilization of the best combination of biomarkers correlated to the stage of sepsis will be 
critical. The current standard for diagnosis of monitoring increased temperature, 
respiratory rate, PaCO2 levels in blood, and abnormal total WBC counts followed by a 1-
3 day bacterial culture leaves huge diagnostic gaps in the treatment pathway [56]. 
Furthermore, these tests cannot be performed frequently to provide sufficient feedback to 
the physician over the course of visits to the ICU. Consequently, a combination of flow 
cytometry with complete blood counts has been utilized in many recent clinical sepsis 
studies [53-59]. Several promising biomarkers measured from these techniques have been 
reported, most notably including neutrophil CD64 cells, neutrophil CD11b cells, band 
neutrophils, platelets, total WBC count, and certain specific lymphocyte populations 
(CD4+ and CD25+) [53-59]. Particularly when combined together, such markers can 
dramatically improve accuracy, sensitivity (>0.9), and specificity (>0.9) of diagnosis at 
early stages of disease. Other blood biomarkers can also indicate the onset of sepsis, 
including C-reactive protein (CRP) and various cytokines (most notably, IL-6). These 
proteins are typically detected via ELISA tests or some variant thereof [60]. 
However, these techniques have yet to find widespread use for the diagnosis of 
sepsis. This is due to several reasons. First, FCM and ELISA assay suffer from a lack of 
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standardization. Reproducible protocols for sample preparation, including RBC lysis, cell 
staining, gating strategies, and acquisition protocols, have proven difficult to keep 
constant for multi-centric clinical studies [60]. Second, FCM, hematology, and protein 
biomarker tests require both a well-equipped laboratory and significant technical 
expertise, which are impossible to obtain 24/7 in ICUs. Third, clinical studies are difficult 
to perform to establish the solidarity of correlations between new biomarkers and disease 
diagnosis, largely due to the former two factors. 
7.1.1. Increased CD64 expression with inflammation  
Cluster of differentiation (CD64) is a high affinity biomarker that binds to 
immunoglobulin G. It is majorly expressed on monocytes but in cases of inflammation, 
CD64 expression will get up-regulated rapidly on neutrophils [61]. During infection or 
inflammation, the increase in the expression of CD64 on neutrophils is stimulated by 
inflammatory cytokines. The intensity of the cytokine stimulus is directly correlated with 
the graded increase in the CD64 expression [61, 62]. However, other studies have also 
shown that increase in the CD64 expression can be activated by either pro inflammatory 
cytokines interferon gamma (IFN-γ) or also granulocyte colony simulating factor (G-
CSF) that are produced in response to the pathogen infection or exposure to endotoxin 
[63, 64]. The increase in the CD64 expression on neutrophils in sepsis cases is higher and 
more specific than other inflammations like autoimmune diseases. One study shows a 
twofold increase in the median CD64 expression in patients with inflammatory 
autoimmune disease as compared to as compared to control patients [65]. However, 
increase in the CD64 expression in the patients with systemic infections was almost 
seven times higher than in the control group [65].   
135	  
	  
7.2. CD64 Expression Quantification Protocol  
To perform sepsis diagnosis using our differential immuno-capture technique, we need to 
show that the specific cell capture in the capture chamber can be correlated to antigen 
expression level. Figure 7.1 shows the CD64 expression quantification protocol. Fifty 
microliters of blood are stained with 50 µL of CD64 FITC conjugated antibodies 
(Trillium Diagnostics, Inc.). The sample is incubated for 15 minutes. The red blood cells 
were lysed with 1mL of 1x lysing buffer and finally 5µL of FITC conjugated CD64 
control beads were added to the solution. The above mentioned sample preparation steps 
for CD64 expression analysis using a flow cytometer are shown in Figure 7.1(a). Figure 
7.1(b) shows the forward and backscatter plot.  There is a clear differentiation between 
total white blood cells, debris and the control beads. The WBC and the beads populations 
were gated and represented by gates R1 and R5 respectively. Figure 7.1(c) shows the 
scatter plot in between 575 (PE) channel and backscatter. The cocktail of the added 
conjugated antibodies also included PE conjugated CD163 Ab. It was used to 
differentiate between monocytes with the lymphocytes and neutrophils by their respective 
gates as shown in Figure 7.1(c).  
The histogram of the monocyte population is obtained at the FITC (530) channel 
representing the CD64 fluorescence intensity. Mean fluorescent intensity (MFI) is 
obtained for monocytes, lymphocytes and neutrophils. Monocytes have high CD64 
expression, resulting in high MFI of 1151. MFI for the neutrophils is around 421 and for 
the lymphocytes MFI is about 103, the result of a result of a non-specific adsorption of 
the antibodies to the lymphocytes.  CD64 FITC conjugated beads in the sample serve as 
an internal control and the MFI of the beads is used to normalize MFI of the different cell 
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types. Figure 7.2 shows the CD64 FITC histogram of monocytes, neutrophils and 
lymphocytes on the 530 channel of the flow cytometer.  
	  
Figure 7.1: CD64 expression quantification protocol. (a) The sample preparation steps for 
CD64 expression analysis using a flow cytometer. (b) Forward and back-scatter plot 
shows the clear differentiation between total white blood cells, debris and the control 
beads. (c) The scatter plot between 575 (PE) channel and backscatter. PE conjugated 
CD163 is used to differentiate between monocytes with the lymphocytes and 
granulocytes.  
100 101 102 103 104
BSC Area
0
10
00
20
00
30
00
40
00
50
00
60
00
FA
LS
 A
re
a
(x
 1
0)
R1: 12.45%
R5: 0.28%
100 101 102 103 104
BSC Area
10
0
10
1
10
2
10
3
10
4
57
5 
A
re
a R4: 72.42%
R6: 9.24%
R7: 16.91%
Blood%% RBC%Lysis%
(Mix)%%
Ab.%Stain% Incubate%%
15%min%
Add%Control%
Beads%
Incubate%%
10%min%
a"
b" c"
WBC"
Beads"
Debris"
Monocyte"
Neutrophil"
Lymphocyte"
137	  
	  
	  
Figure 7.2: The histogram of the FITC (530) channel representing the CD64 fluorescence 
intensity. Monocytes have high CD64 expression, resulting in high mean fluorescence 
intensity (MFI = 1150). MFI for the neutrophils is around 421 and for the lymphocytes 
MFI is about 103, the result of a non-specific adsorption of the antibodies to the 
lymphocytes.   
7.3. CD64 Expression Quantification Using ICU Blood Samples  
We have collected 46 blood samples collected from patients admitted to the intensive 
care unit (ICU) at Carle Hospital, Urbana, IL, and measured the MFI corresponding to 
the CD64 expression on monocytes, lymphocytes and neutrophils using the above 
mentioned protocol. The CD64 FITC conjugated beads in the sample serve as internal 
control; thus, thI neee mean fluorescence intensity ratio is defined as:  
𝑀𝐹𝐼  𝑅𝑎𝑡𝑖𝑜   𝑀𝐹𝐼𝑅 = 𝑀𝑒𝑎𝑛𝐹𝑙𝑜𝑢𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒  𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦  𝑜𝑓  𝑐𝑒𝑙𝑙𝑠𝑀𝑒𝑎𝑛  𝐹𝑙𝑜𝑢𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒  𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦  𝑜𝑓  𝑏𝑒𝑎𝑑𝑠         (7.1) 
Figure 7.3 shows the histogram of the CD64 mean fluorescence intensity ratio of 
cells including monocytes, neutrophils and lymphocytes. Monocytes cover a wide range 
of MFIR from 1.5 to 5. However, CD64 MFIR for neutrophils ranges from around 0.2 to 
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1.2. The high CD64 MFIR for the neutrophil is a possible biomarker for sepsis diagnosis. 
Lymphocytes also show MFIR greater than 0 because of auto-fluorescence or the non-
specific binding of the conjugated antibodies to the cells. 
 
Figure 7.3: Histogram showing the CD64 mean fluorescence intensity ratio of cells 
including monocytes, neutrophils and lymphocytes. The histogram consists of 46 blood 
samples collected from patients admitted to the intensive care unit (ICU).  
In order to perform CD64 expressing cell counting experiments using our 
differential immuno-capture technology, CD64 antigen expression on the monocytes and 
neutrophils needs to be preserved after the treated with saponin and formic acid lysing 
buffer. Two sample preparation protocols for CD64 expression analysis were tested while 
using saponin and formic acid for red blood cell lysis. Figure 7.4(a) shows the pre-lysis 
protocol in which the blood is stained with conjugated Abs before red blood cell lysing 
and quenching steps. Figure 7.4(b) shows the post-lysis protocol in which blood is 
stained with conjugated Abs after red blood cell lysing and quenching steps.  
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Figure 7.4: The sample preparation protocols for CD64 expression analysis while using 
saponin and formic acid for red blood cell lysis. (a) The protocol in which the blood is 
stained with conjugated Abs before red blood cell lysing and quenching steps. (b) Blood 
is stained with conjugated Abs after red blood cell lysing and quenching steps. Lysing 
and quenching steps were performed off-chip.   
Table 7.1 shows the comparison of pre-lysis and post-lysis blood staining protocol 
for CD64 expression quantification while using saponin and formic acid as the lysis 
reagent. MFIR in both protocols is almost the same. However, there is a reduction in 
MFIR of monocytes in the case of post-lysis staining as compared to pre-lysis staining, 
which corresponds to a 12% CD64 expression loss on the monocytes surface. 
Lymphocytes have shown a slight increase in the MFIR in post-Lysis protocol, which can 
be a result of increased non-specific adhesion of CD64 antibodies to the lymphocytes.  
Table 7.1: Comparison of pre-lysis and post-lysis blood staining protocol for CD64 
expression quantification while using saponin and formic acid as the lysis reagent. Lysing 
and quenching steps were performed off-chip. 
 Beads	  MFI Monocyte	  MFI Neutrophil	  MFI Lymphocyte	  MFI 
Pre-­‐lysis	  
staining 
468.36 1983.63	  
MFIR	  =	  4.24 
549.26	  
MFIR	  =	  1.17 
72.05	  
MFIR	  =	  0.15 
Post-­‐lysis	  
staining 
497.35 1752.43	  
MFIR	  =	  3.52	  
575.07	  
MFIR	  =	  1.16 
115.46	  
MFIR	  =	  0.23 
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CD64 expression recovery on the cells with using saponin/ formic acid lysing 
reagent is compared with Trillium kit lysing buffer using 46 blood samples collected 
from patients admitted to ICU at Carle Hospital, Urbana, IL. Post-Lysis protocol was 
selected for this correlation study when lysing the red blood cells with saponin and 
formic acid lysing buffer. Lysing and quenching steps were performed off-chip. 
Monocytes show a good correlation coefficient of R2 = 0.85, with the CD64 MFI ratio 
recovery of almost 85% as shown in Figure 7.5. However, neutrophils show a slight 
increase in fluorescence intensity with saponin/ formic acid lysing with R2 = 0.90 as 
shown in Figure 7.5. The increase in the expression can be the result of slight increase of 
non-specific adsorption of CD64 Abs. on the neutrophils. The MFI ratio for the 
lymphocytes is negligible and is a result of auto-fluorescence and the non-specific 
adsorption of the CD64 Abs. to the cells. Monocytes show a broad range of the mean 
fluorescence intensity ratio, however neutrophils show a narrower range. The measured 
MFI of monocytes or neutrophils is the average MFI of all the acquired cells in the 
solution. Figure 7.5 also shows the respective concentration range for the monocytes and 
neutrophils for all the 46 samples. Ranges of the concentrations of monocytes and 
neutrophils are 40-3000/µL and 1080-20350/µL respectively for all the samples. 
Monocytes are much lower in concentration than neutrophils.   
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Figure 7.5: Comparison of CD64 expression recovery on cells with Trillium kit lysing 
buffer and saponin/ formic acid lysing reagent using patient blood samples admitted to 
ICU (N = 46). Monocytes show a good correlation coefficient of R2 = 0.85, with the 
expression recovery of almost 85%. However, neutrophils show an increase in expression 
with saponin/ formic acid lysing with R2 = 0.90. The increase in the expression can be the 
result of slight increase of non-specific adsorption of CD64 Abs on the neutrophils. The 
MFI ratio for the lymphocytes is negligible and is a result of auto-fluorescence and the 
non-specific adsorption of the CD64 Abs to the cells.  
The Bland-Altman analysis is also used to compare the CD64 MFIR recovery 
using Trillium kit lysing buffer with the saponin/ formic acid lysing reagent (off-chip 
sample preparation). Figure 7.6(a) compares the monocyte CD64 MFIR with both 
techniques and shows a negative bias value of -0.37 with 95% limits of agreement (-1.08 
to 0.34). The bias value shows an average reduction of 0.37 CD64 MFIR on monocytes 
with saponin/ formic acid erythrocyte lysis, which suggest a small reduction of CD64 
antigen expression on the monocytes or the MFIR quantification using post-lysis staining 
protocol.  Figure 7.6(b) compares neutrophils CD64 expression with two techniques and 
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shows a bias value of 0.07 with 95% limits of agreement (-0.023 to 0.164). The bias 
value shows a slight increase in CD64 MFIR on neutrophils due to non-specific 
adsorption with saponin/ formic acid erythrocyte lysis.   
	  
Figure 7.6: The Bland-Altman analysis to compare the CD64 expression using Trillium 
kit lysing buffer with saponin/ formic acid lysing reagent (off-chip sample preparation). 
(a) Monocyte CD64 expression with two techniques shows a bias value of -0.37 with 
95% limits of agreement (-1.08 to 0.34). The bias value shows an average reduction of 
0.37 CD64 MFIR on monocytes with saponin/ formic acid erythrocyte lysis.  (b) 
Neutrophils CD64 expression with two techniques shows a bias value of 0.07 with 95% 
limits of agreement (-0.023 to 0.164). The bias value shows a slight increase in CD64 
MFIR on neutrophils due to non-specific adsorption with saponin/ formic acid 
erythrocyte lysis.   
7.4. CD64 Expression Quantification Using ED Blood Samples  
We have collected 17 blood samples from patients admitted to the emergency department 
(ED) for whom the blood culture is also ordered by the physician at Carle Hospital, 
Urbana, IL, and measured the MFI corresponding to the CD64 expression on monocytes, 
lymphocytes and neutrophils. Figure 7.7 shows the histogram of the CD64 mean 
fluorescence intensity ratio of cells including monocytes, neutrophils and lymphocytes. 
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Monocytes cover a wide range of MFIR from 0.9 to 5. However, CD64 MFIR for 
neutrophils ranges from around 0.2 to 1.2. The high CD64 MFIR for the neutrophil is a 
possible biomarker for sepsis diagnosis. Lymphocytes also show MFIR greater than 0 
because of auto-fluorescence or the non-specific binding of the conjugated antibodies to 
the cells. 
	  
Figure 7.7: The histogram showing the CD64 mean fluorescence intensity ratio of cells 
including monocytes, neutrophils and lymphocytes. The histogram consists of 17 blood 
samples collected from patients for whom the blood culture is also ordered by the 
physician. 
CD64 expression recovery on the cells with using saponin/ formic acid lysing 
reagent is compared with Trillium kit lysing buffer also using 17 blood samples collected 
from patients admitted to the emergency room for whom the blood culture is ordered by 
the physician at Carle Hospital, Urbana, IL. Monocytes show a good correlation 
coefficient of R2 = 0.94 as shown in Figure 7.8. However, neutrophils show a slight 
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increase in expression with saponin/ formic acid lysing with R2 = 0.92 as shown in Figure 
7.8. The increase in the expression can be the result of slight increase of non-specific 
adsorption of CD64 Abs. on the neutrophils. The MFI ratio for the lymphocytes is 
negligible and is a result of auto-fluorescence and the non-specific adsorption of the 
CD64 Abs. to the cells. Monocytes show a broad range of the mean fluorescence 
intensity ratio, however neutrophils show a narrower range. The measured MFI of 
monocytes or neutrophils is the average MFI of all the acquired cells in the solution. 
Figure 7.8 also shows the respective concentration range for the monocytes and 
neutrophils for all the 17 samples. Range of the concentrations of monocytes and 
neutrophils are 10-1990/µL and 120-16340/µL respectively for all the samples. 
Monocytes are much lower in concentration than neutrophils.   
The Bland-Altman analysis is also used to compare the CD64 MFIR recovery 
using Trillium kit lysing buffer with the saponin/ formic acid lysing reagent for these 17 
blood samples. It was obtained by plotting the difference of the two method’s 
measurements with the mean of the two method’s measurements. It generated a bias 
value that indicated a systematic difference in between the measurements and was 
calculated by taking the mean of the difference of the measurements. The limits of 
agreements were calculated by 1.96 × standard deviation of the difference. Two-tailed p-
values were also calculated. Figure 7.9 compares the monocyte CD64 MFIR with both 
techniques and shows a negative bias value of -0.396 with 95% limits of agreement (-
1.32 to 0.53). The bias value shows an average reduction of 0.396 CD64 MFIR on 
monocytes with saponin/ formic acid erythrocyte lysis, which suggests a small reduction 
of CD64 antigen expression on the monocytes or the MFIR quantification using post-
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lysis staining protocol. The slight decreasing trend of the reduced CD64 expression on 
monocytes (using saponin and formic acid lysing reagent) with increasing MFIR is also 
clear from the figure. Figure 7.10 compares neutrophils CD64 expression with two 
techniques and shows a bias value of 0.101 with 95% limits of agreement (0.005 to 
0.197). The bias value shows a slight increase in CD64 MFIR on neutrophils due to non-
specific adsorption with saponin/ formic acid erythrocyte lysis. 
	  
Figure 7.8: Comparison of CD64 expression recovery on cells with Trillium kit lysing 
buffer and saponin/ formic acid lysing reagent using patient blood samples for whom the 
blood culture is also ordered by the physician (N = 17). Monocytes show a good 
correlation coefficient of R2 = 0.942. However, neutrophils show an increase in 
expression with saponin/ formic acid lysing with R2 = 0.915. The increase in the 
expression can be the result of slight increase of non-specific adsorption of CD64 Abs. on 
the neutrophils. The MFI ratio for the lymphocytes is negligible and is a result of auto-
fluorescence and the non-specific adsorption of the CD64 Abs. to the cells.  
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Figure 7.9: The Bland-Altman analysis to compare the CD64 expression using Trillium 
kit lysing buffer with saponin/ formic acid lysing reagent (off-chip sample preparation). 
Monocyte CD64 expression with two techniques shows a bias value of -0.396 with 95% 
limits of agreement (-1.32 to 0.53). The Bias value shows an average reduction of 0.396 
CD64 MFIR on monocytes with saponin/ formic acid erythrocyte lysis. 
	  
Figure 7.10: The Bland-Altman analysis to compare the CD64 expression using Trillium 
kit lysing buffer with saponin/ formic acid lysing reagent (off-chip sample preparation). 
Neutrophils CD64 expression with two techniques shows a bias value of 0.101 with 95% 
limits of agreement (0.005 to 0.197). The bias value shows a slight increase in CD64 
MFIR on neutrophils due to non-specific adsorption with saponin/ formic acid 
erythrocyte lysis.   
!1.5%
!1%
!0.5%
0%
0.5%
1%
0% 1% 2% 3% 4% 5%
CD
64
%M
FI
R%
di
ﬀe
re
nc
e%
of
%sa
po
ni
n/
fo
rm
ic
%a
ci
d%
an
d%
Tr
ill
iu
m
%b
uﬀ
er
%
Average%of%both%methods%(CD64%MFIR)%
Bias%(!0.396)% 95%%limits%of%agreement%(!1.32%to%0.53)%
!0.05%
0%
0.05%
0.1%
0.15%
0.2%
0.25%
0% 0.2% 0.4% 0.6% 0.8% 1% 1.2%CD
64
%M
FI
R%
di
ﬀe
re
nc
e%
of
%sa
po
ni
n/
fo
rm
ic
%a
ci
d%
an
d%
Tr
ill
iu
m
%b
uﬀ
er
%%
Average%of%both%methods%(CD64%MFIR)%
Bias%(0.101)% 95%%limits%of%agreement%(0.005%to%0.197)%
147	  
	  
7.5. Volume Calibration  
To characterize the capture efficiency of CD64 cells in the capture chamber, the 
concentration of the cells needs to be known. The flow cytometers only acquire a 
particular number of events and not the specific volume; we used beads with a known 
concentration (5000 /µL) as an internal control to measure the volume. Figure 7.11 shows 
the forward and back-scatter plot of the sample run through the flow cytometer. The bead 
population is gated and represented by R5. The known concentration of the beads 
allowed us to find the volume of the sample used.  
𝑉𝑜𝑙𝑢𝑚𝑒  𝑎𝑐𝑞𝑢𝑖𝑟𝑒𝑑 = 402  𝑢𝐿10,000×𝑁𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑏𝑒𝑎𝑑𝑠  𝑎𝑐𝑞𝑢𝑖𝑟𝑒𝑑   𝑅5                                                                                           (7.2)	  
	  
Figure 7.11: Forward and back scatter-plot shows the clear differentiation between total 
white blood cells, debris and the control beads. The bead is gated and represented by R5. 
The known concentration of the beads allowed us to find the volume of the sample used.  
The total volume of the solution after performing lysing and quenching was 400 
µL. Two µL of the beads (with a known concentration of 5000 / µL) were added to it. The 
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total resulting volume of the solution is 402 µL with 10,000 beads. Equation 7.2 can be 
used to calculate the volume run through the flow cytometer by counting the number of 
beads acquired from the gate R5. The lymphocytes, monocytes and neutrophils were 
gated on the scatter plot in between 575 (PE) channel and backscatter as shown in Figure 
7.1(c) and the total number of respective cells were found. The resulting volume from 
Equation 7.2 was used to calculate the concentration of the monocytes and neutrophils 
before and after capture to find the capture efficiencies of the respective cells. 
7.6. Specific Cell Capture with CD64 Expression Characterization  
The PDMS capture chamber of height 100 µm with pillars of 40 µm diameter and 17 µm 
spacing between them is coated with the antibodies used in the control assay. After the 
off-chip lysis of the erythrocytes with saponin/ formic acid lysis reagent and quenching, 
the solution is passed through the capture chamber at different flow rates to which the 
antibodies were adsorbed.  Figure 7.12 shows the percentage of captured cells at different 
flow rates with the capture chamber coated with CD64 and CD163 antibodies. The 
percentage of captured monocytes decreased with the increase in the flow rate as shown 
in Figure 7.12(a). At 15 µl/min, the monocytes were captured with highest capture 
efficiency. The percentage of captured neutrophils decreased with the increase in the flow 
rate as shown in Figure 7.12(b). At 15 µL/min, the neutrophil capture efficiency was 
around 60-80%.  
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Figure 7.12: Percentage of captured cells at different flow rates with the capture chamber 
coated with CD64 and CD163 Abs. (a) The % captured monocytes decreased with the 
increase in the flow rate. At 15 µL/min, the monocytes were captured with highest 
efficiency. (b) The % captured neutrophils decreased with the increase in the flow rate. 
At 15 µL/min, the neutrophil capture efficiency was around 60-80%.  
Table 7.1: The mean fluorescence intensity ratio of monocytes and neutrophils for all the 
samples used for the capture experiments.  
Sample Name Monocyte MFIR Neutrophil MFIR 
Sample A 2.11 0.30 
Sample B 2.71 0.31 
Sample C 1.71 0.26 
Sample D 3.64 0.94 
Sample E 3.29 0.46 
Sample F 1.32 0.61 
	  
The percent capture of the CD64 cells in the capture chamber depends on the CD64 
expression level on the cells. Table 7.2 shows the CD64 MFIR for monocytes and 
neutrophils for samples A to F for which the CD64 capture experiments were performed. 
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The change in the percent capture of cells with varying values of CD64 MFIR on cells is 
verified by considering the capture efficiencies of the cells at the flow rate of 15 µL/min. 
Figure 7.13 shows the percentage of captured cells with varying levels of CD64 MFIR on 
monocytes and neutrophils. The percentage of the captured cells increases linearly with 
the increase in CD64 MFIR with a correlation coefficient of R2 = 0.81. The neutrophils 
show a smaller percentage of capture as compared to monocytes, as they express less 
CD64 with reduced CD64 MFIR.    
	  
Figure 7.13: The percentage of captured cells with varying levels of CD64 MFIR. The 
percentage of captured cells increases linearly with the increase in CD64 MFIR with a 
correlation coefficient of R2 = 0.81.   
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CHAPTER 8 
CONCLUSIONS AND FUTURE WORK 
 
8.1. Conclusions 
The field of blood cell counting is expanding at a tremendous rate. People have started 
miniaturizing the automated hematology analyzers into hand-held portable systems. The 
specific cell counting, which is currently done by flow cytometers, needs to be integrated 
with the automated hematology analyzer. A automated hand-held specific blood cell 
counter requires only a drop of blood, i.e. a finger prick. Such a counter will have a 
tremendous impact in all health-care settings of the developed, developing, and resource-
limited regions of the world.  
8.1.1. Complete blood cell count 
In this dissertation work, we have developed microfluidic biochips to count the white 
blood cells, their 3-part differential, red blood cells, platelets and specific leukocytes like 
CD4+ T cells or high expressing CD64 neutrophils. We have lysed the erythrocytes with 
saponin and formic acid and then quenched the lysing process to preserve the remaining 
cells. We have shown that the recovery rates of the total leukocytes, lymphocytes, 
granulocytes + monocytes were 68.35%, 71.83%, 68.02% respectively. The skewness of 
the fitted lognormal distribution to the high-frequency (1.7MHz) granulocyte + monocyte 
distribution correlated well with the control monocyte + eosinophil count. This allowed 
us to count absolute neutrophil and monocyte+ eosinophil separately. We have also 
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shown the red blood cell and the platelet counting on-chip. Platelet counting can be 
further improved by using top and bottom electrodes, which will provide a better 
sensitivity and signal-to-noise ratio for platelet counting. We have compared our biochip 
cell counts with the hematology analyzer counts from the same samples obtained from 
the Carle Foundation Hospital, Urbana, IL, and found a very good correlation between 
both methods.  
8.1.2. Volumetric flow characterization for the biochip 
The volumetric flow measurement will be very useful for the miniaturized biochip. It can 
work as an internal control for the total volume measurement. We have shown that the 
volumetric flow metering based on the change of baseline amplitude shows a high 
correlation. Furthermore, the change in the baseline shift of the ground-referenced signal 
is much higher (20 times) as compared to the change of the baseline amplitude in the 
differential signal. We have also shown that metering can be done by measuring the pulse 
width of the signal. The main advantage of determining the flow rate from the pulse 
width is that the pulse width is independent of the small changes in the ionic 
concentration that may arise due to the difference in red blood cell concentration in the 
blood samples.  
8.1.3. Mathematical analysis of cell counting process 
The mathematical analysis of the cell counting process will help in more accurate 
counting. We characterized the electrical cell counting process in a microfluidic 
impedance cytometer and showed it to be a non-homogenous Poisson process. We 
demonstrated that lymphocytes diffused more in buffer as compared to granulocytes and 
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monocytes. In samples with heterogeneous cell populations, individual cell diffusion 
characteristics should be considered especially if a portion of the sample is being selected 
for accurate counting results. The diffusion analysis can also be used for characterizing 
“push buffer” effectiveness to push the samples that is critical in accurate cell counting. 
We used the Poisson statistics to estimate the sample dilution required for samples with 
high concentrations of cells as this limits the time, throughput, and the volume of the 
reagents used in the device. 
8.1.4. Coincidence detection for heterogeneous cells 
Coincidence detection is very essential for accurate counting results, especially for 
samples with small concentration of target cells. In heterogeneous samples, e.g. in blood, 
cell differentiation in all the coincidence occurrences is essential in addition to the 
coincidence detection for accurate cell enumeration. For example, to count CD4+ T cells 
using our differential immuno-capture technique, the lymphocytes before and after were 
subtracted. In case of the coincidence occurrence, it is important to differentiate a 
lymphocyte from a granulocyte or monocyte. We performed the coincidence 
differentiation characterization and used healthy and HIV infected patient blood samples 
to count the CD4+ and CD8+ T cells, and we have shown that the cell counting with 
coincidence detection gives more accurate results than cell counting without coincidence 
detection. 
8.1.5. CD4+ and CD8+ T cell counting  
 The CD4+ and CD8+ T cells were counted using differential immuno-capture technique. 
We have done CD4 and CD8 capture efficiency characterization and have shown ~90% 
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capture of cells at 0.11 dyn/cm2. Blood samples were collected from healthy and HIV 
infected individuals, and CD4 and CD8 T cells were counted from our biochip. Our 
biochip counts show a very good correlation with the control counts obtained from the 
flow cytometry lab of Carle Hospital for CD4+, CD8+ cells from healthy and HIV 
infected blood samples.   
8.1.6. CD64 expression for sepsis diagnosis  
Elevated levels of CD64 expression on neutrophils are known to be a potential biomarker 
for early sepsis diagnosis. We have shown, using 46 blood samples collected from 
patients admitted to ICU and 17 samples from patients admitted to ED, that our lysing 
and quenching buffer preserves the CD64 expression on neutrophils, however, around 
~80% on monocytes. To use the differential immuno-capture technology for sepsis 
application, we need to measure the percentage of captured CD64 cells in correlation 
with the CD64 expression on the cells. We have done capture optimization studies at 
different flow rates with 6 ICU samples and have shown that the percentages of captured 
monocytes and neutrophils correlate directly with the CD64 MFIR for the respective 
cells.  
8.2. Future Work 
8.2.1. Biomarker discovery for sepsis  
Experiments will be performed to evaluate more biomarkers on cells, e.g. CD11b, CD4, 
CD25 for sepsis diagnosis. CD11b also expressed on neutrophils, however CD4 and 
CD25 is expressed on lymphocytes. As a first step, we will evaluate the expression 
preservation of these antigens on the cells after treating them with our lysing and 
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quenching reagents. We will also evaluate whether other antigens, along with CD64, will 
give us high sensitivity and specificity for early sepsis diagnosis.  
8.2.2. Capture characterization  
We will perform more capture experiments to show that the percent capture of CD64 
neutrophils is different for septic vs. non-septic neutrophils. There is also a potential to 
further enhance the percent cell capture based on expression by changing the adsorption 
surface chemistry to covalent surface chemistry. These experiments will be carried out to 
select the right settings for the capture.  
8.2.3. Reticulocyte counting  
 
Reticulocytes are the immature red blood cells that comprise 1-3% of total cells in 
healthy adults and 3-6% in healthy infants. An abnormally low number of reticulocytes 
can result from chemotherapy, aplastic anemia, pernicious anemia, bone marrow 
malignancies, etc. Reticulocytes are also used to monitor the progress of the treatment of 
anemia. Reticulocytes are slightly larger than normal red blood cells. Figure 8.1 shows 
the amplitude histogram of the cells in diluted blood as they pass through a counting 
channel. The red blood cell amplitude histogram shows another hump, indicated by the 
red arrow. This hump could be a result of a high reticulocyte count. Thus, our red blood 
cell counting technique shows the potential for differentiating and probable counting of 
the reticulocytes in the blood sample.  
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Figure 8.1: The amplitude histogram of the cells in diluted blood as they pass through a 
counting channel. The red blood cell distribution shows another hump, indicated by the 
red arrow. This hump could be a result of a high reticulocyte count.  
8.2.4. On-chip volume metering  
To provide the accurate cell concentration, volume metering is a necessary step. 
However, for a point-of-care CBC counter, especially for a drop of blood from a finger 
prick, on-chip blood volume metering is essential. In future integrated biochip design, we 
will use electrical impedance volumetric flow metering [25]. The microfabricated 
electrodes at both WBC and its 3-part differential section can be used to measure the 10 
µL of blood volume. Similarly, microfabricated electrodes can be used to meter the 1 µL 
volume of blood in the RBC and platelet counting section after blood splitting.  
We have shown in Chapter 3 that, as cells flow through the counter channel, the 
time spacing between the cells follows the exponential distribution characterized by µ 
value. Our mathematical characterization of the cell counting process will allow us to 
measure the inter-cell spacing between the cells, which can in turn be used to perform the 
volume-independent cell concentration measurement.  
Re#culocytes+
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8.2.5. Integrated biochip design  
Figure 8.2 shows the integrated biochip design to count WBC and its differential 
including lymphocytes, granulocytes + monocytes and counting specific cells, e.g. CD64, 
and CD11b for early sepsis diagnosis. 	  
	  
Figure 8.2: Biochip schematic for CBC and CD64, CD11b cell counting for sepsis 
diagnosis.  
The steps of the processes are as follows: 
(i) 11 µL of whole blood is infused at the inlet port. The blood will split in two sections, 
10 µL for WBC and 3-part differential count and 1 µL for RBC and platelet counting.  
(ii) Blood is mixed with PBS to provide the necessary dilution for RBC and platelet 
counting. 
(iii) Microfabricated electrodes will be used to count the RBC and platelets as they pass 
through the counting channel.  
(iv) Blood is mixed with lysing buffer to lyse all the erythrocytes. 
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(v)  Quenching buffer is then infused to halt the lysing process and maintain the pH of 
the solution. 
(vi) The remaining solution will be divided into two equal parts. The cells (total WBC, 
lymphocyte, granulocyte & monocyte) are counted at both the entrance electrodes (a) 
and (b). 
(vii) The CD64 neutrophils will be captured by using CD64 antibody in the capture 
chamber. 
(viii) CD11b Ab is used to capture CD11b neutrophils in the other capture chamber.  
(ix) The remaining cells are counted again at both electrodes (c) and (d). The c-a will 
give the percentage of CD64+ captured cells,  and d-b will give the percent CD11b+ 
captured cells. 	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